| Year |
Citation |
Score |
| 2016 |
Wiebenga OT, Schoonheim MM, Hulst HE, Nagtegaal GJ, Strijbis EM, Steenwijk MD, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ. White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. Ajnr. American Journal of Neuroradiology. PMID 26965463 DOI: 10.3174/Ajnr.A4690 |
0.598 |
|
| 2015 |
Wattjes MP, Rovira À, Miller D, Yousry TA, Sormani MP, de Stefano N, Tintoré M, Auger C, Tur C, Filippi M, Rocca MA, Fazekas F, Kappos L, Polman C, Barkhof F, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nature Reviews. Neurology. PMID 26369511 DOI: 10.1038/Nrneurol.2015.157 |
0.589 |
|
| 2015 |
Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, De Stefano N, Filippi M, Auger C, Rocca MA, Barkhof F, Fazekas F, Kappos L, Polman C, Miller D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nature Reviews. Neurology. 11: 471-82. PMID 26149978 DOI: 10.1038/Nrneurol.2015.106 |
0.595 |
|
| 2015 |
Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 84: 1582-91. PMID 25795646 DOI: 10.1212/Wnl.0000000000001462 |
0.374 |
|
| 2015 |
Wiebenga OT, Klauser AM, Schoonheim MM, Nagtegaal GJ, Steenwijk MD, van Rossum JA, Polman CH, Barkhof F, Pouwels PJ, Geurts JJ. Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. Ajnr. American Journal of Neuroradiology. 36: 1116-23. PMID 25742985 DOI: 10.3174/Ajnr.A4252 |
0.661 |
|
| 2015 |
Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 25662344 DOI: 10.1177/1352458514567728 |
0.322 |
|
| 2015 |
Tewarie P, Schoonheim MM, Schouten DI, Polman CH, Balk LJ, Uitdehaag BM, Geurts JJ, Hillebrand A, Barkhof F, Stam CJ. Functional brain networks: linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG study. Human Brain Mapping. 36: 603-18. PMID 25293505 DOI: 10.1002/Hbm.22650 |
0.632 |
|
| 2015 |
Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 481-4. PMID 25078275 DOI: 10.1177/1352458514541507 |
0.434 |
|
| 2015 |
Bosma LV, Sonder JM, Kragt JJ, Polman CH, Uitdehaag BM. Detecting clinically-relevant changes in progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 171-9. PMID 25013153 DOI: 10.1177/1352458514540969 |
0.479 |
|
| 2015 |
Balk LJ, Steenwijk MD, Tewarie P, Daams M, Killestein J, Wattjes MP, Vrenken H, Barkhof F, Polman CH, Uitdehaag BM, Petzold A. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 86: 419-24. PMID 24973342 DOI: 10.1136/Jnnp-2014-308189 |
0.464 |
|
| 2015 |
Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, de Stefano N, Filippi M, Auger C, Rocca MA, Barkhof F, Fazekas F, Kappos L, Polman C, Miller D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process Nature Reviews Neurology. DOI: 10.1038/nrneurol.2015.106 |
0.319 |
|
| 2014 |
Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM, Lehr L, Stubinski B, Kappos L. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Multiple Sclerosis and Related Disorders. 3: 147-55. PMID 25878002 DOI: 10.1016/J.Msard.2013.07.001 |
0.565 |
|
| 2014 |
Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl C. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Annals of Clinical and Translational Neurology. 1: 605-17. PMID 25285313 DOI: 10.1002/Acn3.91 |
0.5 |
|
| 2014 |
Sonder JM, Balk LJ, van der Linden FA, Bosma LV, Polman CH, Uitdehaag BM. Toward the use of proxy reports for estimating long-term patient-reported outcomes in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 25257617 DOI: 10.1177/1352458514544078 |
0.434 |
|
| 2014 |
Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. Jama Neurology. 71: 1386-93. PMID 25178496 DOI: 10.1001/Jamaneurol.2014.1895 |
0.429 |
|
| 2014 |
Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. European Neurology. 72: 132-41. PMID 25095894 DOI: 10.1159/000360528 |
0.491 |
|
| 2014 |
Tewarie P, Steenwijk MD, Tijms BM, Daams M, Balk LJ, Stam CJ, Uitdehaag BM, Polman CH, Geurts JJ, Barkhof F, Pouwels PJ, Vrenken H, Hillebrand A. Disruption of structural and functional networks in long-standing multiple sclerosis. Human Brain Mapping. 35: 5946-61. PMID 25053254 DOI: 10.1002/Hbm.22596 |
0.641 |
|
| 2014 |
Boeschoten RE, Uitdehaag BM, van Oppen P, de Groot V, Collette EH, Bakker KA, Polman CH, Dekker J. A computer-based screening method for distress in patients with multiple sclerosis: a feasibility study. Jmir Research Protocols. 3: e29. PMID 24902042 DOI: 10.2196/Resprot.3098 |
0.381 |
|
| 2014 |
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, ... ... Polman CH, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 83: 278-86. PMID 24871874 DOI: 10.1212/Wnl.0000000000000560 |
0.551 |
|
| 2014 |
Kilsdonk ID, Lopez-Soriano A, Kuijer JP, de Graaf WL, Castelijns JA, Polman CH, Luijten PR, Geurts JJ, Barkhof F, Wattjes MP. Morphological features of MS lesions on FLAIR* at 7Â T and their relation to patient characteristics. Journal of Neurology. 261: 1356-64. PMID 24777693 DOI: 10.1007/S00415-014-7351-6 |
0.773 |
|
| 2014 |
Tewarie P, Hillebrand A, van Dellen E, Schoonheim MM, Barkhof F, Polman CH, Beaulieu C, Gong G, van Dijk BW, Stam CJ. Structural degree predicts functional network connectivity: a multimodal resting-state fMRI and MEG study. Neuroimage. 97: 296-307. PMID 24769185 DOI: 10.1016/J.Neuroimage.2014.04.038 |
0.369 |
|
| 2014 |
Sonder JM, Balk LJ, Bosma LV, Polman CH, Uitdehaag BM. Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1616-23. PMID 24710798 DOI: 10.1177/1352458514529173 |
0.446 |
|
| 2014 |
Mitjana R, Tintoré M, Rocca MA, Auger C, Barkhof F, Filippi M, Polman C, Fazekas F, Huerga E, Montalban X, Rovira A. Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1471-7. PMID 24576831 DOI: 10.1177/1352458514526083 |
0.541 |
|
| 2014 |
Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. Jama Neurology. 71: 306-14. PMID 24445558 DOI: 10.1001/Jamaneurol.2013.5993 |
0.57 |
|
| 2014 |
Freedman MS, De Stefano N, Barkhof F, Polman CH, Comi G, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Lehr L, Stubinski B, Jack DL, Kappos L. Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study. Journal of Neurology. 261: 490-9. PMID 24413638 DOI: 10.1007/S00415-013-7222-6 |
0.547 |
|
| 2014 |
Balk L, Tewarie P, Killestein J, Polman C, Uitdehaag B, Petzold A. Disease course heterogeneity and OCT in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1198-1206. PMID 24402036 DOI: 10.1177/1352458513518626 |
0.373 |
|
| 2014 |
Kilsdonk ID, Wattjes MP, Lopez-Soriano A, Kuijer JP, de Jong MC, de Graaf WL, Conijn MM, Polman CH, Luijten PR, Geurts JJ, Geerlings MI, Barkhof F. Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. European Radiology. 24: 841-9. PMID 24317461 DOI: 10.1007/S00330-013-3080-Y |
0.694 |
|
| 2014 |
De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM, Hennessy B, Casset-Semanaz F, Lehr L, Stubinski B, Jack DL, Barkhof F. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. Journal of Neurology, Neurosurgery, and Psychiatry. 85: 647-53. PMID 24292999 DOI: 10.1136/Jnnp-2013-306289 |
0.504 |
|
| 2014 |
Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. Journal of Neurology, Neurosurgery, and Psychiatry. 85: 1183-9. PMID 24218527 DOI: 10.1136/Jnnp-2013-306222 |
0.507 |
|
| 2014 |
Tewarie P, Hillebrand A, Schoonheim MM, van Dijk BW, Geurts JJ, Barkhof F, Polman CH, Stam CJ. Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: an MEG source-space study. Neuroimage. 88: 308-18. PMID 24161625 DOI: 10.1016/J.Neuroimage.2013.10.022 |
0.629 |
|
| 2014 |
Sonder JM, Burggraaff J, Knol DL, Polman CH, Uitdehaag BM. Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 481-8. PMID 24019305 DOI: 10.1177/1352458513501570 |
0.39 |
|
| 2014 |
Schoonheim MM, Vigeveno RM, Rueda Lopes FC, Pouwels PJ, Polman CH, Barkhof F, Geurts JJ. Sex-specific extent and severity of white matter damage in multiple sclerosis: implications for cognitive decline. Human Brain Mapping. 35: 2348-58. PMID 23982918 DOI: 10.1002/Hbm.22332 |
0.632 |
|
| 2014 |
van de Kraats C, Killestein J, Popescu V, Rijkers E, Vrenken H, Lütjohann D, Barkhof F, Polman CH, Teunissen CE. Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 412-7. PMID 23959711 DOI: 10.1177/1352458513499421 |
0.585 |
|
| 2014 |
Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D, Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH, Sandbrink R, et al. Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 234-42. PMID 23842212 DOI: 10.1177/1352458513494491 |
0.491 |
|
| 2014 |
van Rossum JA, Vennegoor A, Balk L, Uitdehaag BM, Polman CH, Killestein J. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 108-11. PMID 23828867 DOI: 10.1177/1352458513495582 |
0.345 |
|
| 2014 |
Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, Ruggieri S, Rovira A, Stippich C, Kappos L, Sprenger T, Tortorella P, Rovaris M, Gasperini C, Montalban X, ... ... Polman CH, et al. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 72-80. PMID 23812283 DOI: 10.1177/1352458513492245 |
0.637 |
|
| 2014 |
Hofstetter L, Naegelin Y, Filli L, Kuster P, Traud S, Smieskova R, Mueller-Lenke N, Kappos L, Gass A, Sprenger T, Penner IK, Nichols TE, Vrenken H, Barkhof F, Polman C, et al. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 202-13. PMID 23804554 DOI: 10.1177/1352458513493034 |
0.572 |
|
| 2014 |
Bruinsma I, Eijsink V, Kooi EJ, Baranzini S, Ji XH, Axtell R, Han M, Kuipers H, Sobel R, Polman C, Geurts J, Martens GJM, Poelmans G, Steinman L, Jong BD. Genome-wide RNA expression profiling in human grey and white matter tissue reveals a role for PSA-NCAM dysregulation in MS pathogenesis Journal of Neuroimmunology. 275: 180-181. DOI: 10.1016/J.Jneuroim.2014.08.485 |
0.547 |
|
| 2013 |
Schoonheim M, Geurts J, Wiebenga O, De Munck J, Polman C, Stam C, Barkhof F, Wink A. Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1058-1065. PMID 24347184 DOI: 10.1177/1352458513516892 |
0.636 |
|
| 2013 |
Hulst HE, Gehring K, Uitdehaag BM, Visser LH, Polman CH, Barkhof F, Sitskoorn MM, Geurts JJ. Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI? Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1131-1134. PMID 24277326 DOI: 10.1177/1352458513513969 |
0.628 |
|
| 2013 |
Van der Meer ML, Tewarie P, Schoonheim MM, Douw L, Barkhof F, Polman CH, Stam CJ, Hillebrand A. Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study. Neuroimage. Clinical. 2: 727-34. PMID 24179824 DOI: 10.1016/J.Nicl.2013.05.003 |
0.528 |
|
| 2013 |
Sonder JM, Holman R, Knol DL, Bosma LV, Polman CH, Uitdehaag BM. Analyzing differences between patient and proxy on Patient Reported Outcomes in multiple sclerosis. Journal of the Neurological Sciences. 334: 143-7. PMID 24018128 DOI: 10.1016/J.Jns.2013.08.014 |
0.47 |
|
| 2013 |
Tewarie P, Schoonheim MM, Stam CJ, van der Meer ML, van Dijk BW, Barkhof F, Polman CH, Hillebrand A. Cognitive and clinical dysfunction, altered MEG resting-state networks and thalamic atrophy in multiple sclerosis. Plos One. 8: e69318. PMID 23935983 DOI: 10.1371/Journal.Pone.0069318 |
0.462 |
|
| 2013 |
Lukas C, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, Bendfeldt K, Radue EW, Gass A, Borgwardt SJ, Kappos L, Naegelin Y, Knol DL, Polman CH, Geurts JJ, Barkhof F, et al. Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology. 269: 542-52. PMID 23737540 DOI: 10.1148/Radiol.13122566 |
0.69 |
|
| 2013 |
Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, ... ... Polman CH, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 1082-91. PMID 23524331 DOI: 10.1136/Jnnp-2012-304094 |
0.603 |
|
| 2013 |
Hulst HE, Steenwijk MD, Versteeg A, Pouwels PJ, Vrenken H, Uitdehaag BM, Polman CH, Geurts JJ, Barkhof F. Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. Neurology. 80: 1025-32. PMID 23468546 DOI: 10.1212/Wnl.0B013E31828726Cc |
0.664 |
|
| 2013 |
Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology. 80: 69-75. PMID 23243070 DOI: 10.1212/Wnl.0B013E31827B1A67 |
0.556 |
|
| 2013 |
Kilsdonk ID, de Graaf WL, Soriano AL, Zwanenburg JJ, Visser F, Kuijer JP, Geurts JJ, Pouwels PJ, Polman CH, Castelijns JA, Luijten PR, Barkhof F, Wattjes MP. Multicontrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR. Ajnr. American Journal of Neuroradiology. 34: 791-6. PMID 23042930 DOI: 10.3174/Ajnr.A3289 |
0.714 |
|
| 2013 |
Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 593-600. PMID 22992450 DOI: 10.1177/1352458512460604 |
0.453 |
|
| 2013 |
de Graaf WL, Kilsdonk ID, Lopez-Soriano A, Zwanenburg JJ, Visser F, Polman CH, Castelijns JA, Geurts JJ, Pouwels PJ, Luijten PR, Barkhof F, Wattjes MP. Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. European Radiology. 23: 528-40. PMID 22898935 DOI: 10.1007/S00330-012-2619-7 |
0.735 |
|
| 2013 |
Inkster B, Strijbis EM, Vounou M, Kappos L, Radue EW, Matthews PM, Uitdehaag BM, Barkhof F, Polman CH, Montana G, Geurts JJ. Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. Neurobiology of Aging. 34: 238-47. PMID 22884548 DOI: 10.1016/J.Neurobiolaging.2012.07.007 |
0.646 |
|
| 2013 |
Strijbis EM, Inkster B, Vounou M, Naegelin Y, Kappos L, Radue EW, Matthews PM, Uitdehaag BM, Barkhof F, Polman CH, Montana G, Geurts JJ. Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 281-8. PMID 22851457 DOI: 10.1177/1352458512454345 |
0.653 |
|
| 2013 |
Schoonheim MM, Geurts JJ, Landi D, Douw L, van der Meer ML, Vrenken H, Polman CH, Barkhof F, Stam CJ. Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data. Human Brain Mapping. 34: 52-61. PMID 21954106 DOI: 10.1002/Hbm.21424 |
0.672 |
|
| 2012 |
Schoonheim MM, Popescu V, Rueda Lopes FC, Wiebenga OT, Vrenken H, Douw L, Polman CH, Geurts JJ, Barkhof F. Subcortical atrophy and cognition: sex effects in multiple sclerosis. Neurology. 79: 1754-61. PMID 23019265 DOI: 10.1212/Wnl.0B013E3182703F46 |
0.621 |
|
| 2012 |
Boeschoten RE, Dekker J, Uitdehaag BM, Polman CH, Collette EH, Cuijpers P, Beekman AT, van Oppen P. Internet-based self-help treatment for depression in multiple sclerosis: study protocol of a randomized controlled trial. Bmc Psychiatry. 12: 137. PMID 22967202 DOI: 10.1186/1471-244X-12-137 |
0.38 |
|
| 2012 |
Tewarie P, Teunissen CE, Dijkstra CD, Heijnen DA, Vogt M, Balk L, Vrenken H, Polman CH, Killestein J. Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis. Journal of Neuroimmunology. 251: 103-6. PMID 22858371 DOI: 10.1016/J.Jneuroim.2012.07.002 |
0.503 |
|
| 2012 |
Hardmeier M, Schoonheim MM, Geurts JJ, Hillebrand A, Polman CH, Barkhof F, Stam CJ. Cognitive dysfunction in early multiple sclerosis: altered centrality derived from resting-state functional connectivity using magneto-encephalography. Plos One. 7: e42087. PMID 22848712 DOI: 10.1371/Journal.Pone.0042087 |
0.611 |
|
| 2012 |
Sonder JM, Mokkink LB, van der Linden FA, Polman CH, Uitdehaag BM. Validation and interpretation of the Dutch version of the Multiple Sclerosis Neuropsychological Screening Questionnaire. Journal of the Neurological Sciences. 320: 91-6. PMID 22805106 DOI: 10.1016/J.Jns.2012.06.024 |
0.394 |
|
| 2012 |
Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology. 69: 1259-69. PMID 22751847 DOI: 10.1001/Archneurol.2012.1051 |
0.478 |
|
| 2012 |
Teunissen CE, Sombekke M, van Winsen L, Killestein J, Barkhof F, Polman CH, Dijkstra CD, Blankenstein MA, Pratico D. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 1092-8. PMID 22695538 DOI: 10.1177/1352458511433306 |
0.584 |
|
| 2012 |
Balcer LJ, Galetta SL, Polman CH, Eggenberger E, Calabresi PA, Zhang A, Scanlon JV, Hyde R. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. Journal of the Neurological Sciences. 318: 119-24. PMID 22521274 DOI: 10.1016/J.Jns.2012.03.009 |
0.361 |
|
| 2012 |
Cohen JA, Reingold SC, Polman CH, Wolinsky JS. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. The Lancet. Neurology. 11: 467-76. PMID 22516081 DOI: 10.1016/S1474-4422(12)70059-5 |
0.353 |
|
| 2012 |
Filli L, Hofstetter L, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Kappos L, Gass A, Sprenger T, Nichols TE, Vrenken H, Barkhof F, Polman C, Radue EW, Borgwardt SJ, et al. Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 1577-84. PMID 22495945 DOI: 10.1177/1352458512442756 |
0.586 |
|
| 2012 |
Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink R. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 1466-71. PMID 22492127 DOI: 10.1177/1352458512442438 |
0.49 |
|
| 2012 |
Herges K, de Jong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ko RM, Maini A, Han MH, Killestein J, Polman C, Goodyear AL, Dunn J, Steinman L, Axtell RC. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 398-408. PMID 22343184 DOI: 10.1177/1352458512440060 |
0.326 |
|
| 2012 |
Seewann A, Kooi EJ, Roosendaal SD, Pouwels PJ, Wattjes MP, van der Valk P, Barkhof F, Polman CH, Geurts JJ. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology. 78: 302-8. PMID 22218278 DOI: 10.1212/Wnl.0B013E31824528A0 |
0.601 |
|
| 2012 |
Freedman MS, Metzig C, Kappos L, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Yarden J, Spector L, Fire E, Dotan N, Schwenke S, Lanius V, Sandbrink R, et al. Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 966-73. PMID 22183938 DOI: 10.1177/1352458511432327 |
0.324 |
|
| 2012 |
Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 899-901. PMID 22183929 DOI: 10.1177/1352458511431073 |
0.435 |
|
| 2012 |
Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. The Lancet. Neurology. 11: 33-41. PMID 22146409 DOI: 10.1016/S1474-4422(11)70262-9 |
0.509 |
|
| 2012 |
Barkhof F, Simon JH, Fazekas F, Rovaris M, Kappos L, de Stefano N, Polman CH, Petkau J, Radue EW, Sormani MP, Li DK, O'Connor P, Montalban X, Miller DH, Filippi M. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nature Reviews. Neurology. 8: 13-21. PMID 22143362 DOI: 10.1038/Nrneurol.2011.190 |
0.53 |
|
| 2012 |
Boeschoten RE, Nieuwenhuis MM, van Oppen P, Uitdehaag BM, Polman CH, Collette EH, Cuijpers P, Beekman AT, Dekker J. Feasibility and outcome of a web-based self-help intervention for depressive symptoms in patients with multiple sclerosis: a pilot study. Journal of the Neurological Sciences. 315: 104-9. PMID 22133479 DOI: 10.1016/J.Jns.2011.11.016 |
0.347 |
|
| 2012 |
Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS Journal of Neurology. 259: 898-905. PMID 22008873 DOI: 10.1007/s00415-011-6275-7 |
0.32 |
|
| 2012 |
Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Chitnis S, Polman C, Vosslamber S, Verweij CL, Olsen NJ, Aune TM. Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis. Genes and Immunity. 13: 146-54. PMID 21938015 DOI: 10.1038/Gene.2011.66 |
0.476 |
|
| 2012 |
Schoonheim MM, Hulst HE, Landi D, Ciccarelli O, Roosendaal SD, Sanz-Arigita EJ, Vrenken H, Polman CH, Stam CJ, Barkhof F, Geurts JJ. Gender-related differences in functional connectivity in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 164-73. PMID 21908484 DOI: 10.1177/1352458511422245 |
0.631 |
|
| 2012 |
Sonder JM, Bosma LV, van der Linden FA, Knol DL, Polman CH, Uitdehaag BM. Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 196-201. PMID 21908479 DOI: 10.1177/1352458511417827 |
0.412 |
|
| 2012 |
Hulst HE, Schoonheim MM, Roosendaal SD, Popescu V, Schweren LJ, van der Werf YD, Visser LH, Polman CH, Barkhof F, Geurts JJ. Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis. Human Brain Mapping. 33: 2268-80. PMID 21898674 DOI: 10.1002/Hbm.21359 |
0.627 |
|
| 2012 |
Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, Dawson K, O'Neill GN. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 314-21. PMID 21878455 DOI: 10.1177/1352458511421054 |
0.463 |
|
| 2012 |
de Graaf WL, Zwanenburg JJ, Visser F, Wattjes MP, Pouwels PJ, Geurts JJ, Polman CH, Barkhof F, Luijten PR, Castelijns JA. Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR. European Radiology. 22: 221-31. PMID 21874361 DOI: 10.1007/S00330-011-2242-Z |
0.698 |
|
| 2012 |
Bosma LV, Kragt JJ, Knol DL, Polman CH, Uitdehaag BM. Clinical scales in progressive MS: predicting long-term disability. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 345-50. PMID 21868487 DOI: 10.1177/1352458511419880 |
0.353 |
|
| 2012 |
Kappos L, Radue E, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Jin J, Zhang-Auberson L, Francis G. Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study (S41.004) Neurology. 78: S41.004-S41.004. DOI: 10.1212/Wnl.78.1_Meetingabstracts.S41.004 |
0.355 |
|
| 2011 |
Patsopoulos NA, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, ... ... Polman CH, et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Annals of Neurology. 70: 897-912. PMID 22190364 DOI: 10.1002/Ana.22609 |
0.37 |
|
| 2011 |
Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. The Lancet. Neurology. 10: 1026-34. PMID 22014437 DOI: 10.1016/S1474-4422(11)70228-9 |
0.309 |
|
| 2011 |
Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, et al. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology. 77: 835-43. PMID 21849647 DOI: 10.1212/Wnl.0B013E31822C90D7 |
0.486 |
|
| 2011 |
Kempen JC, de Groot V, Knol DL, Polman CH, Lankhorst GJ, Beckerman H. Community walking can be assessed using a 10-metre timed walk test. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 980-90. PMID 21622593 DOI: 10.1177/1352458511403641 |
0.374 |
|
| 2011 |
Sombekke MH, Jafari N, Bendfeldt K, Mueller-Lenke N, Radue EW, Naegelin Y, Kappos L, Matthews PM, Polman CH, Barkhof F, Hintzen R, Geurts JJ. No influence of KIF1B on neurodegenerative markers in multiple sclerosis. Neurology. 76: 1843-5. PMID 21606458 DOI: 10.1212/Wnl.0B013E31821Cccd4 |
0.612 |
|
| 2011 |
Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, Kappos L, Pelletier D, Hauser SL, Matthews PM, Barkhof F, Geurts JJ. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 1098-106. PMID 21586487 DOI: 10.1177/1352458511404916 |
0.663 |
|
| 2011 |
Seewann A, Vrenken H, Kooi EJ, van der Valk P, Knol DL, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ. Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 1202-10. PMID 21561955 DOI: 10.1177/1352458511406575 |
0.678 |
|
| 2011 |
Sombekke MH, van der Voort LF, Kragt JJ, Nielsen JM, Guzel H, Visser A, Oudejans CB, Crusius JB, Peña AS, Vrenken H, Polman CH, Killestein J. Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 922-30. PMID 21543551 DOI: 10.1177/1352458511402411 |
0.451 |
|
| 2011 |
Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM, Crusius JB, van der Pouw Kraan TC, van der PouwKraan TC, Comabella M, Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, et al. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis. Genes and Immunity. 12: 466-72. PMID 21471993 DOI: 10.1038/Gene.2011.18 |
0.366 |
|
| 2011 |
Sombekke MH, Vellinga MM, Uitdehaag BM, Barkhof F, Polman CH, Arteta D, Tejedor D, Martinez A, Crusius JB, Peña AS, Geurts JJ, Vrenken H. Genetic correlations of brain lesion distribution in multiple sclerosis: an exploratory study. Ajnr. American Journal of Neuroradiology. 32: 695-703. PMID 21436341 DOI: 10.3174/Ajnr.A2352 |
0.637 |
|
| 2011 |
Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 970-9. PMID 21421809 DOI: 10.1177/1352458511399611 |
0.504 |
|
| 2011 |
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology. 69: 292-302. PMID 21387374 DOI: 10.1002/Ana.22366 |
0.384 |
|
| 2011 |
Killestein J, Polman CH. Determinants of interferon β efficacy in patients with multiple sclerosis. Nature Reviews. Neurology. 7: 221-8. PMID 21364522 DOI: 10.1038/Nrneurol.2011.22 |
0.495 |
|
| 2011 |
Hohlfeld R, Barkhof F, Polman C. Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology. 76: S28-37. PMID 21339488 DOI: 10.1212/Wnl.0B013E31820Db40F |
0.536 |
|
| 2011 |
Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 76: 574-6. PMID 21300973 DOI: 10.1212/Wnl.0B013E31820B7644 |
0.535 |
|
| 2011 |
Wang JH, Pappas D, De Jager PL, Pelletier D, de Bakker PI, Kappos L, Polman CH, Chibnik LB, Hafler DA, Matthews PM, Hauser SL, Baranzini SE, Oksenberg JR. Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Medicine. 3: 3. PMID 21244703 DOI: 10.1186/Gm217 |
0.341 |
|
| 2011 |
Rovaris M, Rocca MA, Barkhof F, Calabrese M, De Stefano N, Khalil M, Fazekas F, Fisniku L, Gallo P, Miller DH, Montalban X, Polman C, Rovira A, Sombekke MH, Sormani MP, et al. Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 319-26. PMID 21159719 DOI: 10.1177/1352458510388824 |
0.576 |
|
| 2011 |
Wattjes MP, van Oosten BW, de Graaf WL, Seewann A, Bot JC, van den Berg R, Uitdehaag BM, Polman CH, Barkhof F. No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. Journal of Neurology, Neurosurgery, and Psychiatry. 82: 429-35. PMID 20980483 DOI: 10.1136/Jnnp.2010.223479 |
0.575 |
|
| 2011 |
Kragt JJ, Nielsen JM, van der Linden FA, Polman CH, Uitdehaag BM. Disease progression in multiple sclerosis: combining physicians' and patients' perspectives? Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 234-40. PMID 20978037 DOI: 10.1177/1352458510385505 |
0.443 |
|
| 2011 |
MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, O'Neill GN, Dawson K. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. Journal of Neurology. 258: 449-56. PMID 20963434 DOI: 10.1007/s00415-010-5777-z |
0.346 |
|
| 2011 |
Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer L, Sandbrink R, Kappos L, Uitdehaag BMJ. Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis Bmc Neurology. 11. DOI: 10.1186/1471-2377-11-19 |
0.486 |
|
| 2011 |
Polman CH, Killestein J, Rudick RA. Natalizumab to treat multiple sclerosis Multiple Sclerosis Therapeutics, Fourth Edition. 330-343. DOI: 10.1017/CBO9781139023986.030 |
0.381 |
|
| 2010 |
van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BM, Barkhof F, Oudejans CB, Polman CH, Killestein J. Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology. 75: 1228-33. PMID 20921509 DOI: 10.1212/Wnl.0B013E3181F6C556 |
0.454 |
|
| 2010 |
Worthington V, Killestein J, Eikelenboom MJ, Teunissen CE, Barkhof F, Polman CH, Uitdehaag BM, Petzold A. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology. 75: 1617-22. PMID 20881272 DOI: 10.1212/Wnl.0B013E3181Fb449E |
0.469 |
|
| 2010 |
Coebergh JA, Roosendaal SD, Polman CH, Geurts JJ, van Woerkom TC. Acute severe memory impairment as a presenting symptom of multiple sclerosis: a clinical case study with 3D double inversion recovery MR imaging. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 1521-4. PMID 20846999 DOI: 10.1177/1352458510383302 |
0.602 |
|
| 2010 |
Lukas C, Minneboo A, de Groot V, Moraal B, Knol DL, Polman CH, Barkhof F, Vrenken H. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 81: 1351-6. PMID 20826873 DOI: 10.1136/Jnnp.2009.199968 |
0.579 |
|
| 2010 |
Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Annals of Neurology. 68: 409-11. PMID 20818795 DOI: 10.1002/Ana.22083 |
0.424 |
|
| 2010 |
Morrow SA, O'Connor PW, Polman CH, Goodman AD, Kappos L, Lublin FD, Rudick RA, Jurgensen S, Paes D, Forrestal F, Benedict RH. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 1385-92. PMID 20739335 DOI: 10.1177/1352458510378021 |
0.355 |
|
| 2010 |
Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, E Goelz S. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Annals of Neurology. 68: 304-10. PMID 20737514 DOI: 10.1002/Ana.22107 |
0.325 |
|
| 2010 |
Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, Calabresi PA, Polman C. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. The Lancet. Neurology. 9: 921-32. PMID 20723847 DOI: 10.1016/S1474-4422(10)70168-X |
0.39 |
|
| 2010 |
Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Annals of Neurology. 68: 392-5. PMID 20661928 DOI: 10.1002/Ana.22074 |
0.425 |
|
| 2010 |
Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. The Lancet. Neurology. 9: 740-50. PMID 20610349 DOI: 10.1016/S1474-4422(10)70103-4 |
0.395 |
|
| 2010 |
Nielsen JM, Uitdehaag BM, Korteweg T, Barkhof F, Polman CH. Performance of the Swanton multiple sclerosis criteria for dissemination in space. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 985-7. PMID 20547588 DOI: 10.1177/1352458510369244 |
0.501 |
|
| 2010 |
Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 17: 1019-32. PMID 20528913 DOI: 10.1111/J.1468-1331.2010.03066.X |
0.389 |
|
| 2010 |
Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, Thompson AJ, Tintoré M, Uitdehaag BM. Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 862-7. PMID 20488826 DOI: 10.1177/1352458510370464 |
0.393 |
|
| 2010 |
Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology. 74: S8-15. PMID 20421572 DOI: 10.1212/Wnl.0B013E3181Dbb571 |
0.477 |
|
| 2010 |
Sombekke MH, Arteta D, van de Wiel MA, Crusius JB, Tejedor D, Killestein J, Martínez A, Peña AS, Polman CH, Uitdehaag BM. Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 652-9. PMID 20378664 DOI: 10.1177/1352458510364633 |
0.39 |
|
| 2010 |
van den Elskamp IJ, Knol DL, Vrenken H, Karas G, Meijerman A, Filippi M, Kappos L, Fazekas F, Wagner K, Pohl C, Sandbrink R, Polman CH, Uitdehaag BM, Barkhof F. Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 660-9. PMID 20350960 DOI: 10.1177/1352458510364630 |
0.52 |
|
| 2010 |
Tallantyre EC, Bø L, Al-Rawashdeh O, Owens T, Polman CH, Lowe JS, Evangelou N. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 406-11. PMID 20215480 DOI: 10.1177/1352458510364992 |
0.364 |
|
| 2010 |
Lazzarino G, Amorini AM, Eikelenboom MJ, Killestein J, Belli A, Di Pietro V, Tavazzi B, Barkhof F, Polman CH, Uitdehaag BM, Petzold A. Cerebrospinal fluid ATP metabolites in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 549-54. PMID 20194579 DOI: 10.1177/1352458510364196 |
0.416 |
|
| 2010 |
Jakkula E, Leppä V, Sulonen AM, Varilo T, Kallio S, Kemppinen A, Purcell S, Koivisto K, Tienari P, Sumelahti ML, Elovaara I, Pirttilä T, Reunanen M, Aromaa A, Oturai AB, ... ... Polman C, et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. American Journal of Human Genetics. 86: 285-91. PMID 20159113 DOI: 10.1016/J.Ajhg.2010.01.017 |
0.38 |
|
| 2010 |
van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, Killestein J. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Archives of Neurology. 67: 402-7. PMID 20142519 DOI: 10.1001/Archneurol.2010.21 |
0.367 |
|
| 2010 |
van Winsen LM, Polman CH, Dijkstra CD, Tilders FJ, Uitdehaag BM. Suppressive effect of glucocorticoids on TNF-alpha production is associated with their clinical effect in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 500-2. PMID 20086025 DOI: 10.1177/1352458509359721 |
0.372 |
|
| 2010 |
Vogt MH, ten Kate J, Drent RJ, Polman CH, Hupperts R. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 443-9. PMID 20086024 DOI: 10.1177/1352458509359723 |
0.343 |
|
| 2010 |
van Winsen LM, Kragt JJ, Hoogervorst EL, Polman CH, Uitdehaag BM. Outcome measurement in multiple sclerosis: detection of clinically relevant improvement. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 604-10. PMID 20086019 DOI: 10.1177/1352458509359922 |
0.369 |
|
| 2010 |
van den Elskamp IJ, Boden B, Dattola V, Knol DL, Filippi M, Kappos L, Fazekas F, Wagner K, Pohl C, Sandbrink R, Polman CH, Uitdehaag BM, Barkhof F. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology. 52: 875-81. PMID 20049424 DOI: 10.1007/S00234-009-0645-1 |
0.55 |
|
| 2010 |
Vrenken H, Seewann A, Knol DL, Polman CH, Barkhof F, Geurts JJ. Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. Ajnr. American Journal of Neuroradiology. 31: 541-8. PMID 19850760 DOI: 10.3174/Ajnr.A1839 |
0.661 |
|
| 2010 |
de Graaf W, Visser F, Wattjes M, Zwanenburg J, Pouwels P, Geurts J, Polman C, Barkhof F, Luijten P, Castelijns J. 7 Tesla 3D-MP-FLAIR and 3D-MP-DIR: Lesion Detection in Multiple Sclerosis RöFo - Fortschritte Auf Dem Gebiet Der RöNtgenstrahlen Und Der Bildgebenden Verfahren. 182. DOI: 10.1055/S-0030-1268258 |
0.525 |
|
| 2009 |
Sombekke MH, Lukas C, Crusius JB, Tejedor D, Killestein J, Arteta D, MartÃnez A, Uitdehaag BM, Knol DL, Peña AS, Geurts JJ, De Jager PL, Barkhof F, Vrenken H, Polman CH. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Archives of Neurology. 66: 1531-6. PMID 20008659 DOI: 10.1001/Archneurol.2009.278 |
0.627 |
|
| 2009 |
Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Téllez N, Vellinga MM, Tur C, Brochet B, Barkhof F, Rovaris M, Miller DH, Polman CH, Rovira A, Thompson AJ. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 1459-65. PMID 19995843 DOI: 10.1177/1352458509348422 |
0.372 |
|
| 2009 |
Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP, Kappos L, Miller DH, Montalban X, Lanius V, Sandbrink R, Barkhof F. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Archives of Neurology. 66: 1345-52. PMID 19901165 DOI: 10.1001/Archneurol.2009.243 |
0.48 |
|
| 2009 |
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. The Lancet. Neurology. 8: 987-97. PMID 19748319 DOI: 10.1016/S1474-4422(09)70237-6 |
0.474 |
|
| 2009 |
de Groot V, Beckerman H, Uitdehaag BM, Hintzen RQ, Minneboo A, Heymans MW, Lankhorst GJ, Polman CH, Bouter LM. Physical and cognitive functioning after 3 years can be predicted using information from the diagnostic process in recently diagnosed multiple sclerosis. Archives of Physical Medicine and Rehabilitation. 90: 1478-88. PMID 19735774 DOI: 10.1016/J.Apmr.2009.03.018 |
0.418 |
|
| 2009 |
Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW. Assessing disability progression with the Multiple Sclerosis Functional Composite. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 984-97. PMID 19667023 DOI: 10.1177/1352458509106212 |
0.301 |
|
| 2009 |
Eikelenboom MJ, Killestein J, Kragt JJ, Uitdehaag BM, Polman CH. Gender differences in multiple sclerosis: cytokines and vitamin D. Journal of the Neurological Sciences. 286: 40-2. PMID 19656528 DOI: 10.1016/J.Jns.2009.06.025 |
0.424 |
|
| 2009 |
De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S, Baranzini SE, McCauley JL, ... ... Polman C, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nature Genetics. 41: 776-82. PMID 19525953 DOI: 10.1038/Ng.401 |
0.395 |
|
| 2009 |
van der Voort LF, Visser A, Knol DL, Oudejans CB, Polman CH, Killestein J. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 16: 1049-52. PMID 19486142 DOI: 10.1111/J.1468-1331.2009.02649.X |
0.396 |
|
| 2009 |
Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer L, Sandbrink R, Kappos L, Uitdehaag BM. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. Bmc Neurology. 9: 19. PMID 19457248 DOI: 10.1186/1471-2377-9-19 |
0.568 |
|
| 2009 |
Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. The Lancet. Neurology. 8: 545-59. PMID 19446274 DOI: 10.1016/S1474-4422(09)70082-1 |
0.369 |
|
| 2009 |
Seewann A, Vrenken H, van der Valk P, Blezer EL, Knol DL, Castelijns JA, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. Archives of Neurology. 66: 601-9. PMID 19433660 DOI: 10.1001/Archneurol.2009.57 |
0.751 |
|
| 2009 |
Rovira A, Swanton J, Tintoré M, Huerga E, Barkhof F, Filippi M, Frederiksen JL, Langkilde A, Miszkiel K, Polman C, Rovaris M, Sastre-Garriga J, Miller D, Montalban X. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Archives of Neurology. 66: 587-92. PMID 19433658 DOI: 10.1001/archneurol.2009.49 |
0.32 |
|
| 2009 |
Korteweg T, Tintore M, Uitdehaag BMJ, Knol DL, Vrenken H, Rovira A, Frederiksen J, Miller DH, Fernando K, Filippi M, Agosta F, Rocca MA, Fazekas F, Enzinger C, Parry A, ... Polman CH, et al. A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome European Radiology. 19: 2244-2248. PMID 19415295 DOI: 10.1007/S00330-009-1402-X |
0.5 |
|
| 2009 |
Minneboo A, Uitdehaag BM, Jongen P, Vrenken H, Knol Dl, van Walderveen MA, Polman CH, Castelijns JA, Barkhof F. Association between MRI parameters and the MS severity scale: a 12 year follow-up study. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 632-7. PMID 19389751 DOI: 10.1177/1352458509102617 |
0.719 |
|
| 2009 |
Bosma LVAE, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, Thompson AJ, Tintoré M, Uitdehaag BMJ. The search for responsive clinical endpoints in primary progressive multiple sclerosis Multiple Sclerosis. 15: 715-720. PMID 19383646 DOI: 10.1177/1352458509102626 |
0.403 |
|
| 2009 |
Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman C, D'Urso S, Vagnozzi R, Uitdehaag B, Lazzarino G. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clinical Biochemistry. 42: 1001-6. PMID 19341721 DOI: 10.1016/j.clinbiochem.2009.03.020 |
0.324 |
|
| 2009 |
van Winsen LM, Manenschijn L, van Rossum EF, Crusius JB, Crusius BA, Koper JW, Polman CH, Uitdehaag BM. A glucocorticoid receptor gene haplotype (TthIII1/ER22/23EK/9beta) is associated with a more aggressive disease course in multiple sclerosis. The Journal of Clinical Endocrinology and Metabolism. 94: 2110-4. PMID 19318444 DOI: 10.1210/Jc.2008-2194 |
0.415 |
|
| 2009 |
van der Linden FA, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BM. The size of the treatment effect: do patients and proxies agree? Bmc Neurology. 9: 12. PMID 19317921 DOI: 10.1186/1471-2377-9-12 |
0.401 |
|
| 2009 |
Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology. 256: 405-15. PMID 19308305 DOI: 10.1007/S00415-009-0093-1 |
0.393 |
|
| 2009 |
Vellinga MM, Vrenken H, Hulst HE, Polman CH, Uitdehaag BM, Pouwels PJ, Barkhof F, Geurts JJ. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. Journal of Magnetic Resonance Imaging : Jmri. 29: 774-9. PMID 19306366 DOI: 10.1002/Jmri.21678 |
0.715 |
|
| 2009 |
Vellinga MM, Geurts JJ, Rostrup E, Uitdehaag BM, Polman CH, Barkhof F, Vrenken H. Clinical correlations of brain lesion distribution in multiple sclerosis. Journal of Magnetic Resonance Imaging : Jmri. 29: 768-73. PMID 19306365 DOI: 10.1002/Jmri.21679 |
0.643 |
|
| 2009 |
Baranzini SE, Galwey NW, Wang J, Khankhanian P, Lindberg R, Pelletier D, Wu W, Uitdehaag BM, Kappos L, Polman CH, Matthews PM, Hauser SL, Gibson RA, Oksenberg JR, et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Human Molecular Genetics. 18: 2078-90. PMID 19286671 DOI: 10.1093/Hmg/Ddp120 |
0.404 |
|
| 2009 |
Thompson A, Polman C. Improving function: a new treatment era for multiple sclerosis? Lancet (London, England). 373: 697-8. PMID 19249614 DOI: 10.1016/S0140-6736(09)60414-1 |
0.374 |
|
| 2009 |
Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. The Lancet. Neurology. 8: 254-60. PMID 19201654 DOI: 10.1016/S1474-4422(09)70021-3 |
0.445 |
|
| 2009 |
Killestein J, Polman CH. [Alemtuzumab in early multiple sclerosis]. Nederlands Tijdschrift Voor Geneeskunde. 153: 46. PMID 19198214 |
0.347 |
|
| 2009 |
Korteweg T, Rovaris M, Neacsu V, Filippi M, Comi G, Uitdehaag BM, Knol DL, Polman CH, Barkhof F, Vrenken H, Polman C, Montalban X, Rovira A, Miller D, Thompson A, et al. Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? Multiple Sclerosis. 15: 465-471. PMID 19091881 DOI: 10.1177/1352458508100505 |
0.514 |
|
| 2009 |
Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, ... ... Polman CH, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics. 18: 767-78. PMID 19010793 DOI: 10.1093/Hmg/Ddn388 |
0.658 |
|
| 2009 |
Altmann DR, Jasperse B, Barkhof F, Beckmann K, Filippi M, Kappos LD, Molyneux P, Polman CH, Pozzilli C, Thompson AJ, Wagner K, Yousry TA, Miller DH. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis Neurology. 72: 595-601. PMID 19005170 DOI: 10.1212/01.Wnl.0000335765.55346.Fc |
0.43 |
|
| 2009 |
van der Voort LF, Kok A, Visser A, Oudejans CB, Caldano M, Gilli F, Bertolotto A, Polman CH, Killestein J. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 212-8. PMID 18805837 DOI: 10.1177/1352458508096877 |
0.32 |
|
| 2009 |
Kragt JJ, van Amerongen BM, Killestein J, Dijkstra CD, Uitdehaag BMJ, Polman CH, Lips P. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women Multiple Sclerosis. 15: 9-15. PMID 18701572 DOI: 10.1177/1352458508095920 |
0.453 |
|
| 2009 |
Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, et al. Erratum: The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL (Journal of Neurology (2009) 256 (405-415) DOI: 10.1007/s00415-009-0093-1) Journal of Neurology. 256: 1035-1037. DOI: 10.1007/S00415-009-5183-6 |
0.428 |
|
| 2009 |
Lukas C, Minneboo A, Groot Vd, Moraal B, Polman C, Barkhof F, Vrenken H. Direkte und indirekte Verfahren zur Quantifizierung der zerebralen Atrophie bei MS Nervenarzt. 80: 14-15. DOI: 10.1007/S00115-009-2769-2 |
0.553 |
|
| 2008 |
Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 372: 1463-72. PMID 18970976 DOI: 10.1016/S0140-6736(08)61619-0 |
0.404 |
|
| 2008 |
Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, ... ... Polman CH, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 1157-74. PMID 18805839 DOI: 10.1177/1352458508096878 |
0.377 |
|
| 2008 |
Teunissen CE, Killestein J, Kragt JJ, Polman CH, Dijkstra CD, Blom HJ. Serum homocysteine levels in relation to clinical progression in multiple sclerosis Journal of Neurology, Neurosurgery and Psychiatry. 79: 1349-1353. PMID 18676406 DOI: 10.1136/Jnnp.2008.151555 |
0.436 |
|
| 2008 |
Van Der Linden FAH, D'Hooghe MB, Nagels G, Van Nunen A, Polman CH, Uitdehaag BMJ. Proxy ratings from multiple sources: Disagreement on the impact of multiple sclerosis on daily life European Journal of Neurology. 15: 933-939. PMID 18637034 DOI: 10.1111/j.1468-1331.2008.02224.x |
0.341 |
|
| 2008 |
Pronk J, Scheper G, van Andel R, van Berkel C, Polman Ch, Uitdehaag B, van der Knaap M. No evidence that polymorphisms of the vanishing white matter disease genes are risk factors in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 1123-6. PMID 18632786 DOI: 10.1177/1352458508093618 |
0.494 |
|
| 2008 |
Nielsen JM, Uitdehaag BM, Polman CH. Long-term follow-up of suspected though unconfirmed MS. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 985-7. PMID 18573831 DOI: 10.1177/1352458508090922 |
0.475 |
|
| 2008 |
Khaleeli Z, Ciccarelli O, Manfredonia F, Barkhof F, Brochet B, Cercignani M, Dousset V, Filippi M, Montalban X, Polman C, Rovaris M, Rovira A, Sastre-Garriga J, Vellinga M, Miller D, et al. Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. Annals of Neurology. 63: 790-3. PMID 18383506 DOI: 10.1002/Ana.21375 |
0.48 |
|
| 2008 |
van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. Plos One. 3: e1927. PMID 18382694 DOI: 10.1371/Journal.Pone.0001927 |
0.473 |
|
| 2008 |
Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 70: 1134-40. PMID 18362273 DOI: 10.1212/01.Wnl.0000306410.84794.4D |
0.474 |
|
| 2008 |
van der Linden FA, Kragt JJ, van Bon M, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BM. Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years. Bmc Neurology. 8: 2. PMID 18307788 DOI: 10.1186/1471-2377-8-2 |
0.456 |
|
| 2008 |
Rocca MA, Agosta F, Sormani MP, Fernando K, Tintorè M, Korteweg T, Tortorella P, Miller DH, Thompson A, Rovira A, Montalban X, Polman C, Barkhof F, Filippi M. A three-year, multi-parametric MRI study in patients at presentation with CIS. Journal of Neurology. 255: 683-91. PMID 18274802 DOI: 10.1007/S00415-008-0776-Z |
0.58 |
|
| 2008 |
Vellinga MM, Oude Engberink RD, Seewann A, Pouwels PJ, Wattjes MP, van der Pol SM, Pering C, Polman CH, de Vries HE, Geurts JJ, Barkhof F. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain : a Journal of Neurology. 131: 800-7. PMID 18245785 DOI: 10.1093/Brain/Awn009 |
0.608 |
|
| 2008 |
Geurts JJ, Blezer EL, Vrenken H, van der Toorn A, Castelijns JA, Polman CH, Pouwels PJ, Bö L, Barkhof F. Does high-field MR imaging improve cortical lesion detection in multiple sclerosis? Journal of Neurology. 255: 183-91. PMID 18231704 DOI: 10.1007/S00415-008-0620-5 |
0.708 |
|
| 2008 |
Zwemmer JNP, Bot JCJ, Jelles B, Barkhof F, Polman CH. At the heart of primary progressive multiple sclerosis: Three cases with diffuse MRI abnormalities only Multiple Sclerosis. 14: 428-430. PMID 18208890 DOI: 10.1177/1352458507084591 |
0.537 |
|
| 2008 |
Rovaris M, Judica E, Sastre-Garriga J, Rovira A, Sormani MP, Benedetti B, Korteweg T, Stefano ND, Khaleeli Z, Montalban X, Barkhof F, Miller DH, Polman C, Thompson AJ, Filippi M. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Multiple Sclerosis Journal. 14: 455-464. PMID 18208869 DOI: 10.1177/1352458507085129 |
0.56 |
|
| 2008 |
Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BMJ. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS Neurology. 70: 1084-1091. PMID 18184917 DOI: 10.1212/01.wnl.0000288179.86056.e1 |
0.397 |
|
| 2008 |
Polman CH. Early diagnosis of multiple sclerosis-still a challenge? Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 2-3. PMID 18089670 DOI: 10.1177/1352458507082721 |
0.398 |
|
| 2008 |
Minneboo A, Jasperse B, Barkhof F, Uitdehaag BM, Knol DL, de Groot V, Polman CH, Castelijns JA. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. Journal of Neurology, Neurosurgery, and Psychiatry. 79: 917-23. PMID 18077480 DOI: 10.1136/Jnnp.2007.124123 |
0.655 |
|
| 2008 |
Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. Journal of Neurology. 255: 480-7. PMID 18004635 DOI: 10.1007/S00415-007-0733-2 |
0.557 |
|
| 2008 |
Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 70: 1150-1. PMID 17872364 DOI: 10.1212/01.Wnl.0000265393.03231.E5 |
0.677 |
|
| 2007 |
Jasperse B, Valsasina P, Neacsu V, Knol DL, De Stefano N, Enzinger C, Smith SM, Ropele S, Korteweg T, Giorgio A, Anderson V, Polman CH, Filippi M, Miller DH, Rovaris M, et al. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. Journal of Magnetic Resonance Imaging : Jmri. 26: 881-5. PMID 17896359 DOI: 10.1002/Jmri.21101 |
0.53 |
|
| 2007 |
Jasperse B, Vrenken H, Sanz-Arigita E, de Groot V, Smith SM, Polman CH, Barkhof F. Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. Neuroimage. 38: 529-37. PMID 17889567 DOI: 10.1016/J.Neuroimage.2007.07.056 |
0.499 |
|
| 2007 |
van Veen T, Nielsen J, Berkhof J, Barkhof F, Kamphorst W, Bö L, Ravid R, Verweij CL, Huitinga I, Polman CH, Uitdehaag BM. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. Journal of Neuroimmunology. 190: 157-64. PMID 17884183 DOI: 10.1016/J.Jneuroim.2007.08.005 |
0.574 |
|
| 2007 |
Liedorp M, Sanchez E, Van Hoogstraten IMW, Von Blomberg BME, Barkhof F, Polman CH, Killestein J. No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up Journal of Neurology, Neurosurgery and Psychiatry. 78: 1146-1148. PMID 17878195 DOI: 10.1136/Jnnp.2007.117713 |
0.446 |
|
| 2007 |
Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Poppe P, de Vos M, Lasri F, Bauer L, Dahms S, Wagner K, et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Archives of Neurology. 64: 1292-8. PMID 17846268 DOI: 10.1001/Archneur.64.9.1292 |
0.5 |
|
| 2007 |
Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Annals of Neurology. 62: 335-46. PMID 17696126 DOI: 10.1002/Ana.21163 |
0.427 |
|
| 2007 |
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet (London, England). 370: 389-97. PMID 17679016 DOI: 10.1016/S0140-6736(07)61194-5 |
0.52 |
|
| 2007 |
Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, Huerga E, Miszkiel KA, Plant GT, Polman C, Rovaris M, Thompson AJ, Montalban X, Miller DH. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurology. 6: 677-686. PMID 17616439 DOI: 10.1016/S1474-4422(07)70176-X |
0.532 |
|
| 2007 |
Nielsen JM, Moraal B, Polman CH, Poppe P, de Vos M, Freedman MS, Kappos L, Barjhof F, Bauer L, Pohl C, Sandbrink R, Hartung HP, Uitdehaag BMJ. Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results Multiple Sclerosis. 13: 717-721. PMID 17613598 DOI: 10.1177/1352458506074684 |
0.439 |
|
| 2007 |
Vrenken H, Pouwels PJ, Ropele S, Knol DL, Geurts JJ, Polman CH, Barkhof F, Castelijns JA. Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Multiple Sclerosis (Houndmills, Basingstoke, England). 13: 708-16. PMID 17613597 DOI: 10.1177/1352458506075521 |
0.776 |
|
| 2007 |
Hartung H, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, et al. Neutralising antibodies to interferon β in multiple sclerosis Journal of Neurology. 254: 827-837. PMID 17457510 DOI: 10.1007/S00415-006-0486-3 |
0.393 |
|
| 2007 |
Jasperse B, Jakobs C, Eikelenboom MJ, Dijkstra CD, Uitdehaag BM, Barkhof F, Polman CH, Teunissen CE. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. Journal of Neurology. 254: 631-7. PMID 17415509 DOI: 10.1007/S00415-006-0415-5 |
0.595 |
|
| 2007 |
Kalkers NF, Strijers RL, Jasperse MM, Neacsu V, Geurts JJ, Barkhof F, Polman CH, Stam CJ. Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI. Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 118: 1332-40. PMID 17398151 DOI: 10.1016/J.Clinph.2007.02.018 |
0.666 |
|
| 2007 |
van Winsen LML, Hooper-van Veen T, van Rossum EFC, Koper JW, Barkhof F, Polman CH, Uitdehaag BMJ. Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS Journal of Neuroimmunology. 186: 150-155. PMID 17395275 DOI: 10.1016/J.Jneuroim.2007.02.006 |
0.528 |
|
| 2007 |
Jasperse B, Minneboo A, de Groot V, Kalkers NF, van Helden PE, Uitdehaag BM, Barkhof F, Polman CH. Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. Archives of Neurology. 64: 190-4. PMID 17296834 DOI: 10.1001/Archneur.64.2.190 |
0.557 |
|
| 2007 |
Soon D, Altmann DR, Fernando KT, Giovannoni G, Barkhof F, Polman CH, O'Connor P, Gray B, Panzara M, Miller DH. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. Journal of Neurology. 254: 306-14. PMID 17277910 DOI: 10.1007/S00415-006-0356-Z |
0.455 |
|
| 2007 |
Janssens AC, Buljevac D, van Doorn PA, van der Meché FG, Polman CH, Passchier J, Hintzen RQ. Prediction of anxiety and distress following diagnosis of multiple sclerosis: a two-year longitudinal study. Multiple Sclerosis (Houndmills, Basingstoke, England). 12: 794-801. PMID 17263009 DOI: 10.1177/1352458506070935 |
0.304 |
|
| 2007 |
Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. The New England Journal of Medicine. 356: 371-8. PMID 17251533 DOI: 10.1056/Nejmoa063602 |
0.572 |
|
| 2007 |
Bö L, Geurts JJ, van der Valk P, Polman C, Barkhof F. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Archives of Neurology. 64: 76-80. PMID 17210812 DOI: 10.1001/Archneur.64.1.76 |
0.687 |
|
| 2007 |
Korteweg T, Uitdehaag BM, Knol DL, Smithuis RH, Algra PR, de Vries C, Poppe PA, van Waesberghe JH, Bergers E, Lycklama à Nijeholt GJ, Polman CH, Barkhof F. Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. European Radiology. 17: 67-71. PMID 16708216 DOI: 10.1007/S00330-006-0303-5 |
0.541 |
|
| 2007 |
Kappos L, Montalban X, Hartung H, Freedman M, Polman C. Treating clinically isolated syndromes suggestive of MS – Authors' reply The Lancet. 370: 2000-2001. DOI: 10.1016/S0140-6736(07)61855-8 |
0.41 |
|
| 2006 |
Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Jongen PJH, Polman C, Uitdehaag B. Costs and quality of life in multiple sclerosis in The Netherlands European Journal of Health Economics. 8: 359-359. PMID 17310343 DOI: 10.1007/S10198-006-0378-6 |
0.338 |
|
| 2006 |
Lazeron RHC, Sonneville LMJd, Scheltens P, Polman CH, Barkhof F. Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. Multiple Sclerosis Journal. 12: 760-768. PMID 17263004 DOI: 10.1177/1352458506070924 |
0.56 |
|
| 2006 |
Zwemmer JN, Berkhof J, Castelijns JA, Barkhof F, Polman CH, Uitdehaag BM. Classification of multiple sclerosis patients by latent class analysis of magnetic resonance imaging characteristics. Multiple Sclerosis (Houndmills, Basingstoke, England). 12: 565-72. PMID 17086901 DOI: 10.1177/1352458506070759 |
0.717 |
|
| 2006 |
Vrenken H, Geurts JJ, Knol DL, Polman CH, Castelijns JA, Pouwels PJ, Barkhof F. Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis. Ajnr. American Journal of Neuroradiology. 27: 2005-11. PMID 17032884 |
0.72 |
|
| 2006 |
Charil A, Yousry TA, Rovaris M, Barkhof F, De Stefano N, Fazekas F, Miller DH, Montalban X, Simon JH, Polman C, Filippi M. MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". The Lancet. Neurology. 5: 841-52. PMID 16987731 DOI: 10.1016/S1474-4422(06)70572-5 |
0.557 |
|
| 2006 |
Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclerosis. The New England Journal of Medicine. 355: 1124-40. PMID 16971719 DOI: 10.1056/Nejmoa052643 |
0.423 |
|
| 2006 |
Young PJ, Lederer C, Eder K, Daumer M, Neiss A, Polman C, Kappos L. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology. 67: 804-8. PMID 16966541 DOI: 10.1212/01.Wnl.0000234064.17156.03 |
0.479 |
|
| 2006 |
Nielsen JM, Barkhof F, van Oosten BW, Polman CH. The role of spinal cord imaging in the diagnosis of multiple sclerosis. Nature Clinical Practice. Neurology. 2: 283-6; quiz 287. PMID 16932565 DOI: 10.1038/Ncpneuro0169 |
0.509 |
|
| 2006 |
Vrenken H, Geurts JJ, Knol DL, van Dijk LN, Dattola V, Jasperse B, van Schijndel RA, Polman CH, Castelijns JA, Barkhof F, Pouwels PJ. Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. Radiology. 240: 811-20. PMID 16868279 DOI: 10.1148/Radiol.2403050569 |
0.768 |
|
| 2006 |
Noort JMv, Verbeek R, Meilof JF, Polman CH, Amor S. Autoantibodies against alpha B-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire. Multiple Sclerosis Journal. 12: 287-293. PMID 16764341 DOI: 10.1191/135248506Ms1271Oa |
0.342 |
|
| 2006 |
Breij EC, Heijnen P, van der Goes A, Teunissen CE, Polman CH, Dijkstra CD. Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients. Journal of Neuroimmunology. 176: 106-14. PMID 16712958 DOI: 10.1016/J.Jneuroim.2006.03.014 |
0.378 |
|
| 2006 |
Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Polman CH. Cognitive impairment and decline in different MS subtypes. Journal of the Neurological Sciences. 245: 187-94. PMID 16643951 DOI: 10.1016/J.Jns.2005.07.018 |
0.434 |
|
| 2006 |
Hooper-van Veen T, Berkhof J, Polman CH, Uitdehaag BM. Analysing the effect of candidate genes on complex traits: an application in multiple sclerosis. Immunogenetics. 58: 347-54. PMID 16612628 DOI: 10.1007/S00251-006-0116-3 |
0.371 |
|
| 2006 |
Vrenken H, Pouwels PJ, Geurts JJ, Knol DL, Polman CH, Barkhof F, Castelijns JA. Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. Journal of Magnetic Resonance Imaging : Jmri. 23: 628-36. PMID 16565955 DOI: 10.1002/Jmri.20564 |
0.759 |
|
| 2006 |
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. The New England Journal of Medicine. 354: 899-910. PMID 16510744 DOI: 10.1056/Nejmoa044397 |
0.433 |
|
| 2006 |
Korteweg T, Tintoré M, Uitdehaag B, Rovira A, Frederiksen J, Miller D, Fernando K, Filippi M, Agosta F, Rocca M, Fazekas F, Enzinger C, Matthews P, Parry A, Polman C, et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. The Lancet. Neurology. 5: 221-7. PMID 16488377 DOI: 10.1016/S1474-4422(06)70353-2 |
0.5 |
|
| 2006 |
Geurts JJ, Reuling IE, Vrenken H, Uitdehaag BM, Polman CH, Castelijns JA, Barkhof F, Pouwels PJ. MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 55: 478-83. PMID 16463353 DOI: 10.1002/Mrm.20792 |
0.764 |
|
| 2006 |
Cover KS, Vrenken H, Geurts JJ, van Oosten BW, Jelles B, Polman CH, Stam CJ, van Dijk BW. Multiple sclerosis patients show a highly significant decrease in alpha band interhemispheric synchronization measured using MEG. Neuroimage. 29: 783-8. PMID 16226894 DOI: 10.1016/J.Neuroimage.2005.08.048 |
0.607 |
|
| 2006 |
Giovannoni G, O'Connor P, Havrdova E, Hutchinson M, Kappos L, Miller D, Phillips JT, Polman C, Lublin F, Wajgt A, Lynn F, Panzara M, Sandrock A. Sa.32. The Immunogenicity of Natalizumab in Patients with Multiple Sclerosis Clinical Immunology. 119: S116. DOI: 10.1016/J.Clim.2006.04.264 |
0.479 |
|
| 2005 |
Groot Vd, Beckerman H, Lankhorst GJ, Polman CH, Bouter LM. The initial course of daily functioning in multiple sclerosis: A three-year follow-up study Multiple Sclerosis Journal. 11: 713-718. PMID 16320733 DOI: 10.1191/1352458505Ms1238Oa |
0.349 |
|
| 2005 |
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology. 58: 840-6. PMID 16283615 DOI: 10.1002/Ana.20703 |
0.47 |
|
| 2005 |
Nielsen JM, Korteweg T, Barkhof F, Uitdehaag BM, Polman CH. Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Annals of Neurology. 58: 781-3. PMID 16240352 DOI: 10.1002/Ana.20632 |
0.583 |
|
| 2005 |
Lazeron RH, Boringa JB, Schouten M, Uitdehaag BM, Bergers E, Lindeboom J, Eikelenboom MI, Scheltens PH, Barkhof F, Polman CH. Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 11: 524-31. PMID 16193889 DOI: 10.1191/1352458505Ms1201Oa |
0.546 |
|
| 2005 |
Scherder E, Wolters E, Polman C, Sergeant J, Swaab D. Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems. Neuroscience and Biobehavioral Reviews. 29: 1047-56. PMID 16143170 DOI: 10.1016/J.Neubiorev.2005.03.001 |
0.33 |
|
| 2005 |
van Winsen LL, Hooper-van Veen T, van Rossum EF, Polman CH, van den Berg TK, Koper JW, Uitdehaag BM. The impact of glucocorticoid receptor gene polymorphisms on glucocorticoid sensitivity is outweighted in patients with multiple sclerosis. Journal of Neuroimmunology. 167: 150-6. PMID 16083972 DOI: 10.1016/J.Jneuroim.2005.06.010 |
0.42 |
|
| 2005 |
Sormani MP, Bruzzi P, Beckmann K, Kappos L, Miller DH, Polman C, Pozzilli C, Thompson AJ, Wagner K, Filippi M. The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis Journal of Neurology. 252: 1455-1458. PMID 16021360 DOI: 10.1007/S00415-005-0885-X |
0.517 |
|
| 2005 |
Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology. 236: 254-60. PMID 15987979 DOI: 10.1148/Radiol.2361040450 |
0.728 |
|
| 2005 |
Killestein J, Kalkers NF, Polman CH. Glutamate inhibition in MS: the neuroprotective properties of riluzole. Journal of the Neurological Sciences. 233: 113-5. PMID 15949499 DOI: 10.1016/J.Jns.2005.03.011 |
0.449 |
|
| 2005 |
Killestein J, Polman CH. Current trials in multiple sclerosis: established evidence and future hopes. Current Opinion in Neurology. 18: 253-60. PMID 15891408 DOI: 10.1097/01.Wco.0000169741.29535.Cc |
0.383 |
|
| 2005 |
Uitdehaag BM, Kappos L, Bauer L, Freedman MS, Miller D, Sandbrink R, Polman CH. Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Multiple Sclerosis (Houndmills, Basingstoke, England). 11: 227-31. PMID 15794398 DOI: 10.1191/1352458505Ms1149Oa |
0.486 |
|
| 2005 |
Korteweg T, Barkhof F, Uitdehaag BM, Polman CH. How to use spinal cord magnetic resonance imaging in the McDonald diagnostic criteria for multiple sclerosis. Annals of Neurology. 57: 606-7. PMID 15786460 DOI: 10.1002/Ana.20412 |
0.457 |
|
| 2005 |
Geurts JJ, Bö L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. Ajnr. American Journal of Neuroradiology. 26: 572-7. PMID 15760868 |
0.706 |
|
| 2005 |
Fabriek BO, Zwemmer JN, Teunissen CE, Dijkstra CD, Polman CH, Laman JD, Castelijns JA. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. Journal of Neuroimmunology. 161: 190-4. PMID 15748959 DOI: 10.1016/J.Jneuroim.2004.12.018 |
0.621 |
|
| 2005 |
Polman CH, Wolinsky JS, Reingold SC. Multiple sclerosis diagnostic criteria: three years later Multiple Sclerosis Journal. 11: 5-12. PMID 15732260 DOI: 10.1191/1352458505Ms1135Oa |
0.475 |
|
| 2005 |
Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, Pouwels PJ. MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 53: 256-66. PMID 15678547 DOI: 10.1002/Mrm.20366 |
0.714 |
|
| 2005 |
Visschedijk MA, Collette EH, Polman CH, Pfennings LE, van der Ploeg HM. Development of a cognitive behavioral group intervention programme for patients with multiple sclerosis: an exploratory study. Psychological Reports. 95: 735-46. PMID 15666900 DOI: 10.2466/Pr0.95.3.735-746 |
0.414 |
|
| 2005 |
Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeron RH, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. Journal of Neurology, Neurosurgery, and Psychiatry. 76: 206-11. PMID 15654034 DOI: 10.1136/Jnnp.2004.043315 |
0.395 |
|
| 2005 |
Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis Lancet Neurology. 4: 32-41. PMID 15620855 DOI: 10.1016/S1474-4422(04)00964-0 |
0.415 |
|
| 2005 |
Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, Baars PA, van Lier RA, Barkhof F, Uitdehaag BM, Polman CH. Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. Journal of Neuroimmunology. 158: 222-30. PMID 15589057 DOI: 10.1016/J.Jneuroim.2004.09.005 |
0.471 |
|
| 2005 |
Winsen LMLv, Muris DFR, Polman CH, Dijkstra CD, Berg TKvd, Uitdehaag BMJ. Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. The Journal of Clinical Endocrinology and Metabolism. 90: 734-740. PMID 15546910 DOI: 10.1210/Jc.2004-0306 |
0.48 |
|
| 2005 |
Hoogervorst EL, Zwemmer JN, Jelles B, Polman CH, Uitdehaag BM. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability. Multiple Sclerosis (Houndmills, Basingstoke, England). 10: 569-74. PMID 15471375 DOI: 10.1191/1352458504ms1078oa |
0.321 |
|
| 2005 |
Lazeron RH, Rombouts SA, Scheltens P, Polman CH, Barkhof F. An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 10: 549-55. PMID 15471372 DOI: 10.1191/1352458504Ms1072Oa |
0.637 |
|
| 2005 |
Schrijver HM, Crusius JB, García-González MA, Polman CH, Peña AS, Barkhof F, Uitdehaag BM. Gender-related association between the TGFB1+869 polymorphism and multiple sclerosis. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 24: 536-42. PMID 15450129 DOI: 10.1089/Jir.2004.24.536 |
0.508 |
|
| 2005 |
Killestein J, Polman C. The therapeutic value of cannabinoids in MS: real or imaginary? Multiple Sclerosis (Houndmills, Basingstoke, England). 10: 339-40. PMID 15327026 DOI: 10.1191/1352458504Ms1064Ed |
0.428 |
|
| 2004 |
Kragt JJ, Hoogervorst ELJ, Uitdehaag BMJ, Polman CH. Relation between objective and subjective measures of bladder dysfunction in multiple sclerosis. Neurology. 63: 1716-1718. PMID 15534265 DOI: 10.1212/01.Wnl.0000143062.43325.C8 |
0.428 |
|
| 2004 |
Rejdak K, Eikelenboom MJ, Petzold A, Thompson EJ, Stelmasiak Z, Lazeron RH, Barkhof F, Polman CH, Uitdehaag BM, Giovannoni G. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology. 63: 1439-45. PMID 15505162 DOI: 10.1212/01.Wnl.0000142043.32578.5D |
0.518 |
|
| 2004 |
Uitdehaag BM, Geurts JJ, Barkhof F, Polman CH. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee. Neurology. 63: 1140; author reply 1. PMID 15452328 |
0.549 |
|
| 2004 |
Bot JC, Blezer EL, Kamphorst W, Lycklama A Nijeholt GJ, Ader HJ, Castelijns JA, Ig KN, Bergers E, Ravid R, Polman C, Barkhof F. The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. Radiology. 233: 531-40. PMID 15385682 DOI: 10.1148/Radiol.2332031572 |
0.679 |
|
| 2004 |
Geurts JJ, Barkhof F, Castelijns JA, Uitdehaag BM, Polman CH, Pouwels PJ. Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility. Journal of Magnetic Resonance Imaging : Jmri. 20: 366-71. PMID 15332241 DOI: 10.1002/Jmri.20138 |
0.675 |
|
| 2004 |
van Oosten BW, Killestein J, Mathus-Vliegen EM, Polman CH. Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Multiple Sclerosis (Houndmills, Basingstoke, England). 10: 330-1. PMID 15222701 DOI: 10.1191/1352458504ms1044oa |
0.331 |
|
| 2004 |
Zwemmer JN, Veen Tv, Winsen Lv, Kamp GJv, Barkhof F, Polman CH, Uitdehaag BM. No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. Multiple Sclerosis Journal. 10: 272-277. PMID 15222690 DOI: 10.1191/1352458504Ms1010Oa |
0.556 |
|
| 2004 |
Polman CH, Killestein J. Statins for the treatment of multiple sclerosis: cautious hope. Lancet (London, England). 363: 1570. PMID 15145628 DOI: 10.1016/S0140-6736(04)16237-5 |
0.418 |
|
| 2004 |
Jonge Pd, Hoogervorst ELJ, Huyse FJ, Polman CH. INTERMED: a measure of biopsychosocial case complexity: one year stability in Multiple Sclerosis patients General Hospital Psychiatry. 26: 147-152. PMID 15038933 DOI: 10.1016/J.Genhosppsych.2003.09.001 |
0.389 |
|
| 2004 |
Floris S, Goes Avd, Killestein J, Knol DL, Barkhof F, Polman CH, Dijkstra CD, Vries HEd, Meilof JF. Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels. Journal of Neuroimmunology. 148: 172-177. PMID 14975598 DOI: 10.1016/J.Jneuroim.2003.11.005 |
0.567 |
|
| 2004 |
Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Archives of Neurology. 61: 217-21. PMID 14967769 DOI: 10.1001/Archneur.61.2.217 |
0.65 |
|
| 2004 |
Polman CH, Wolinsky JS, Reingold SC. Multiple sclerosis: should MR criteria for dissemination in time be less stringent. Annals of Neurology. 55: 297. PMID 14755738 DOI: 10.1002/Ana.10856 |
0.464 |
|
| 2004 |
Killestein J, Uitdehaag BM, Polman CH. Cannabinoids in multiple sclerosis: do they have a therapeutic role? Drugs. 64: 1-11. PMID 14723555 DOI: 10.2165/00003495-200464010-00001 |
0.473 |
|
| 2004 |
Hooper-van Veen T, Schrijver HM, Zwiers A, Crusius JB, Knol DL, Kalkers NF, Laine ML, Barkhof F, Peña AS, Polman CH, Uitdehaag BM. The interleukin-1 gene family in multiple sclerosis susceptibility and disease course. Multiple Sclerosis (Houndmills, Basingstoke, England). 9: 535-9. PMID 14664464 DOI: 10.1191/1352458503Ms974Oa |
0.524 |
|
| 2004 |
van Walderveen MA, van Schijndel RA, Pouwels PJ, Polman CH, Barkhof F. Multislice T1 relaxation time measurements in the brain using IR-EPI: reproducibility, normal values, and histogram analysis in patients with multiple sclerosis. Journal of Magnetic Resonance Imaging : Jmri. 18: 656-64. PMID 14635150 DOI: 10.1002/Jmri.10417 |
0.548 |
|
| 2004 |
Killestein J, Eikelenboom MJ, Izeboud T, Kalkers NF, Adèr HJ, Barkhof F, Van Lier RA, Uitdehaag BM, Polman CH. Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS. Journal of Neuroimmunology. 142: 141-8. PMID 14512173 DOI: 10.1016/S0165-5728(03)00265-0 |
0.461 |
|
| 2004 |
Hoogervorst EL, de Jonge P, Jelles B, Huyse FJ, Heeres I, van der Ploeg HM, Uitdehaag BM, Polman CH. The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment. Journal of Neurology, Neurosurgery, and Psychiatry. 74: 20-4. PMID 12486260 DOI: 10.1136/jnnp.74.1.20 |
0.318 |
|
| 2004 |
Neuhaus A, Augustin T, Daumer M, Kappos L, Kuechenhoff H, Polman C. P2.57: Modelling Time to Progression in Multiple Sclerosis Biometrical Journal. 46: 149-149. DOI: 10.1002/Bimj.200490210 |
0.376 |
|
| 2003 |
Polman CH, Jansen PHP, Jansen C, Uitdehaag BMJ. A rare, treatable cause of relapsing encephalopathy in an MS patient on interferon beta therapy. Neurology. 61: 719-719. PMID 12963780 DOI: 10.1212/Wnl.61.5.719 |
0.447 |
|
| 2003 |
Killestein J, Polman CH. Cannabis use in multiple sclerosis: excited interest. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 30: 181-2. PMID 12945937 DOI: 10.1017/S0317167100002547 |
0.382 |
|
| 2003 |
Polman CH, Uitdehaag BM. New and emerging treatment options for multiple sclerosis. The Lancet. Neurology. 2: 563-6. PMID 12941579 DOI: 10.1016/S1474-4422(03)00505-2 |
0.487 |
|
| 2003 |
Lycklama G, Thompson A, Filippi M, Miller D, Polman C, Fazekas F, Barkhof F. Spinal-cord MRI in multiple sclerosis. The Lancet. Neurology. 2: 555-62. PMID 12941578 DOI: 10.1016/S1474-4422(03)00504-0 |
0.466 |
|
| 2003 |
Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, van der Valk P. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Archives of Neurology. 60: 1073-81. PMID 12925362 DOI: 10.1001/Archneur.60.8.1073 |
0.66 |
|
| 2003 |
Teunissen CE, Dijkstra CD, Polman CH, Hoogervorst EL, von Bergmann K, Lütjohann D. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neuroscience Letters. 347: 159-62. PMID 12875910 DOI: 10.1016/S0304-3940(03)00667-0 |
0.405 |
|
| 2003 |
Veen Tv, Crusius JBA, Winsen Lv, Xia B, Barkhof F, Peña AS, Polman CH, Uitdehaag BMJ. CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis. Journal of Neuroimmunology. 140: 188-193. PMID 12864988 DOI: 10.1016/S0165-5728(03)00184-X |
0.556 |
|
| 2003 |
't Hart BA, Vogels JT, Spijksma G, Brok HP, Polman C, van der Greef J. 1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. Journal of the Neurological Sciences. 212: 21-30. PMID 12809995 DOI: 10.1016/S0022-510X(03)00080-7 |
0.423 |
|
| 2003 |
Geurts JJ, Wolswijk G, Bö L, van der Valk P, Polman CH, Troost D, Aronica E. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain : a Journal of Neurology. 126: 1755-66. PMID 12805104 DOI: 10.1093/Brain/Awg179 |
0.509 |
|
| 2003 |
Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Annals of Neurology. 53: 819-22. PMID 12783433 DOI: 10.1002/Ana.10606 |
0.485 |
|
| 2003 |
Lopatinskaya L, van Boxel-Dezaire AH, Barkhof F, Polman CH, Lucas CJ, Nagelkerken L. The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. Journal of Neuroimmunology. 138: 123-31. PMID 12742662 DOI: 10.1016/S0165-5728(03)00089-4 |
0.489 |
|
| 2003 |
Polman CH, Uitdehaag BN, Klok AM. Ocular comorbidity in multiple sclerosis. Lancet (London, England). 361: 1230. PMID 12686079 DOI: 10.1016/S0140-6736(03)12945-5 |
0.47 |
|
| 2003 |
Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R, Rice GP. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet (London, England). 361: 545-52. PMID 12598138 DOI: 10.1016/S0140-6736(03)12512-3 |
0.411 |
|
| 2003 |
Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Multiple Sclerosis (Houndmills, Basingstoke, England). 8: 532-3. PMID 12474997 DOI: 10.1191/1352458502Ms849Xx |
0.481 |
|
| 2003 |
Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, van Lier RA, Barkhof F, Uitdehaag BM, Polman CH. Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. Journal of Neuroimmunology. 133: 225-32. PMID 12446027 DOI: 10.1016/S0165-5728(02)00374-0 |
0.456 |
|
| 2002 |
Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Archives of Neurology. 59: 1572-6. PMID 12374494 DOI: 10.1001/Archneur.59.10.1572 |
0.53 |
|
| 2002 |
Bergers E, Bot JC, van der Valk P, Castelijns JA, Lycklama a Nijeholt GJ, Kamphorst W, Polman CH, Blezer EL, Nicolay K, Ravid R, Barkhof F. Diffuse signal abnormalities in the spinal cord in multiple sclerosis: direct postmortem in situ magnetic resonance imaging correlated with in vitro high-resolution magnetic resonance imaging and histopathology. Annals of Neurology. 51: 652-6. PMID 12112117 DOI: 10.1002/Ana.10170 |
0.62 |
|
| 2002 |
Veen Tv, Kalkers NF, Crusius JB, Winsen LMLv, Barkhof F, Jongen PJH, Pena AS, Polman CH, Uitdehaag BMJ. The FAS-670 polymorphism influences susceptibility to multiple sclerosis. Journal of Neuroimmunology. 128: 95-100. PMID 12098516 DOI: 10.1016/S0165-5728(02)00163-7 |
0.559 |
|
| 2002 |
Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, Cuzner ML, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain : a Journal of Neurology. 125: 1462-73. PMID 12076997 DOI: 10.1093/Brain/Awf165 |
0.49 |
|
| 2002 |
De Sonneville LM, Boringa JB, Reuling IE, Lazeron RH, Adèr HJ, Polman CH. Information processing characteristics in subtypes of multiple sclerosis. Neuropsychologia. 40: 1751-65. PMID 12062887 DOI: 10.1016/S0028-3932(02)00041-6 |
0.366 |
|
| 2002 |
Bot JC, Barkhof F, Lycklama à Nijeholt G, van Schaardenburg D, Voskuyl AE, Ader HJ, Pijnenburg JA, Polman CH, Uitdehaag BM, Vermeulen EG, Castelijns JA. Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology. 223: 46-56. PMID 11930047 DOI: 10.1148/Radiol.2231010707 |
0.702 |
|
| 2002 |
Killestein J, Olsson T, Wallström E, Svenningsson A, Khademi M, Blumhardt LD, Fagius J, Hillert J, Landtblom AM, Edenius C, Arfors L, Barkhof F, Polman CH. Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. Annals of Neurology. 51: 467-74. PMID 11921052 DOI: 10.1002/Ana.10146 |
0.536 |
|
| 2002 |
Hoogervorst ELJ, Kalkers NF, Uitdehaag BMJ, Polman CH. A Study Validating Changes in the Multiple Sclerosis Functional Composite Jama Neurology. 59: 113-116. PMID 11790238 DOI: 10.1001/Archneur.59.1.113 |
0.388 |
|
| 2001 |
Bruggen MAMvd, Huisman HBM, Beckerman H, Bertelsmann FW, Polman CH, Lankhorst GJ. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. Journal of Neurology. 248: 665-671. PMID 11569894 DOI: 10.1007/S004150170111 |
0.301 |
|
| 2001 |
Veen TV, Crusius JBA, Schrijver HM, Bouma G, Killestein J, Winsen LV, Peña AS, Polman CH, Uitdehaag BMJ. Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis. Annals of Neurology. 50: 275-275. PMID 11506417 DOI: 10.1002/Ana.1107 |
0.35 |
|
| 2001 |
Killestein J, Rep MH, Barkhof F, Roos MT, Adèr HJ, van Lier RA, Polman CH. Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells. Journal of Neuroimmunology. 118: 286-94. PMID 11498263 DOI: 10.1016/S0165-5728(01)00346-0 |
0.497 |
|
| 2001 |
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology. 50: 121-7. PMID 11456302 DOI: 10.1002/Ana.1032 |
0.517 |
|
| 2001 |
Barkhof F, van Waesberghe JH, Filippi M, Yousry T, Miller DH, Hahn D, Thompson AJ, Kappos L, Brex P, Pozzilli C, Polman CH. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain : a Journal of Neurology. 124: 1396-402. PMID 11408334 DOI: 10.1093/Brain/124.7.1396 |
0.545 |
|
| 2001 |
van Walderveen MA, Lycklama A Nijeholt GJ, Adèr HJ, Jongen PJ, Polman CH, Castelijns JA, Barkhof F. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Archives of Neurology. 58: 76-81. PMID 11176939 DOI: 10.1001/Archneur.58.1.76 |
0.739 |
|
| 2001 |
Kalkers NF, Bergers L, Groot Vd, Lazeron RHC, Walderveen MAAv, Uitdehaag BMJ, Polman CH, Barkhof F. Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology. 56: 215-219. PMID 11160958 DOI: 10.1212/Wnl.56.2.215 |
0.557 |
|
| 2001 |
Visschedijk M, Pfennings L, Collette E, Jelles B, Polman C, van der Ploeg H. Een kortdurende groepsinterventie voor mensen met multiple sclerose, enkele eerste indrukken Dth. 21: 80-86. DOI: 10.1007/Bf03060256 |
0.42 |
|
| 2000 |
Polman CH, Uitdehaag BMJ. Drug treatment of multiple sclerosis Western Journal of Medicine. 173: 398-402. PMID 11112758 DOI: 10.1136/Ewjm.173.6.398 |
0.379 |
|
| 2000 |
Polman CH, Uitdehaag BMJ. Drug treatment of multiple sclerosis. Bmj. 321: 490-494. PMID 10948033 DOI: 10.1136/Bmj.321.7259.490 |
0.426 |
|
| 2000 |
Lycklama à Nijeholt GJ, Castelijns JA, Lazeron RH, van Waesberghe JH, Polman CH, Uitdehaag BM, Barkhof F. Magnetization transfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disability. Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. 10: 67-72. PMID 10800258 DOI: 10.1111/Jon200010267 |
0.648 |
|
| 2000 |
Tan IL, Lycklama à Nijeholt GJ, Polman CH, Adèr HJ, Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Multiple Sclerosis (Houndmills, Basingstoke, England). 6: 99-104. PMID 10773855 DOI: 10.1177/135245850000600208 |
0.453 |
|
| 2000 |
Morré SA, Groot CJAD, Killestein J, Meijer CJLM, Polman CH, Valk PVD, Brule AJCVD. Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients Annals of Neurology. 48: 399-399. DOI: 10.1002/1531-8249(200009)48:3<399::Aid-Ana19>3.0.Co;2-3 |
0.464 |
|
| 1999 |
Pfennings LEMA, Cohen L, Miller D, Gerbaud L, Vleugels L, Freeman JA, Vernay D, Biolay S, Ketelaer P, Thompson AJ, Polman CH, Ploeg HMvd. Using the Short Form-36 with Multiple Sclerosis Patients in Five Countries: A Cross-Cultural Comparison: Psychological Reports. 85: 19-31. PMID 10575971 DOI: 10.2466/Pr0.1999.85.1.19 |
0.351 |
|
| 1999 |
Pfennings LEMA, Ploeg HMvd, Cohen L, Polman CH. A comparison of responsiveness indices in multiple sclerosis patients. Quality of Life Research. 8: 481-489. PMID 10548863 DOI: 10.1023/A:1008971904852 |
0.312 |
|
| 1999 |
van Walderveen MA, Barkhof F, Pouwels PJ, van Schijndel RA, Polman CH, Castelijns JA. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Annals of Neurology. 46: 79-87. PMID 10401783 DOI: 10.1002/1531-8249(199907)46:1<79::Aid-Ana12>3.0.Co;2-9 |
0.668 |
|
| 1999 |
Rep MHG, Schrijver HM, Lopik Tv, Hintzen RQ, Roos MTL, Adèr HJ, Polman CH, Lier RAWv. Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patients Journal of Neuroimmunology. 96: 92-100. PMID 10227428 DOI: 10.1016/S0165-5728(98)00271-9 |
0.312 |
|
| 1999 |
Nasseri K, Uitdehaag BMJ, Walderveen MAAv, Ader HJ, Polman CH. Cardiovascular autonomic function in patients with relapsing remitting multiple sclerosis: a new surrogate marker of disease evolution? European Journal of Neurology. 6: 29-33. PMID 10209346 DOI: 10.1046/J.1468-1331.1999.610029.X |
0.537 |
|
| 1999 |
Van Walderveen MAA, Truyen L, Van Oosten BW, Castelijns JA, Lycklama À Nijeholt GJ, Van Waesberghe JHTM, Polman C, Barkhof F. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: Relation to inflammatory activity Archives of Neurology. 56: 345-351. PMID 10190826 DOI: 10.1001/Archneur.56.3.345 |
0.647 |
|
| 1999 |
van Oosten BW, Truyen L, Barkhof F, Polman CH. Choosing drug therapy for multiple sclerosis. An update. Drugs. 56: 555-69. PMID 9806103 DOI: 10.2165/00003495-199856040-00004 |
0.516 |
|
| 1998 |
Pfennings L, Cohen L, Ploeg HVD, Polman C, Lankhorst G. Reliability of two measures of health-related quality of life in patients with multiple sclerosis. Perceptual and Motor Skills. 87: 111-114. PMID 9760635 DOI: 10.2466/Pms.1998.87.1.111 |
0.364 |
|
| 1998 |
van Oosten BW, Barkhof F, Scholten PE, von Blomberg BM, Adèr HJ, Polman CH. Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis. Archives of Neurology. 55: 793-8. PMID 9626770 DOI: 10.1001/Archneur.55.6.793 |
0.461 |
|
| 1998 |
Vleugels L, Pfennings L, Pouwer F, Cohen L, Ketelaer P, Polman C, Lankhorst G, Ploeg H. Psychological functioning in primary progressive versus secondary progressive multiple sclerosis British Journal of Medical Psychology. 71: 99-106. PMID 9561309 DOI: 10.1111/J.2044-8341.1998.Tb01370.X |
0.488 |
|
| 1998 |
Hintzen RQ, Polman CH. Th-cell modulation in multiple sclerosis. Immunology Today. 18: 507-8. PMID 9357146 DOI: 10.1016/S0167-5699(97)82526-1 |
0.355 |
|
| 1997 |
Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Adèr HJ, Losseff N, Valk J. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain : a Journal of Neurology. 120: 2059-69. PMID 9397021 DOI: 10.1093/Brain/120.11.2059 |
0.624 |
|
| 1997 |
Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Montalban XFM, Sá JD. Primary Progressive Multiple Sclerosis Brain. 120: 1085-1096. PMID 9217691 DOI: 10.1093/Brain/120.6.1085 |
0.457 |
|
| 1997 |
van Waesberghe JH, Castelijns JA, Scheltens P, Truyen L, Lycklana A Nijeholt GJ, Hoogenraad FG, Polman CH, Valk J, Barkhof F. Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. Magnetic Resonance Imaging. 15: 155-62. PMID 9106143 DOI: 10.1016/S0730-725X(96)00340-2 |
0.707 |
|
| 1997 |
Barkhof F, Polman C. Oral or intravenous methylprednisolone for acute relapses of MS? Lancet (London, England). 349: 893-4. PMID 9093245 DOI: 10.1016/S0140-6736(05)62691-8 |
0.517 |
|
| 1996 |
Uitdehaag BM, Polman CH, Sontrop K, Dijkstra CD. The effect of the 21-aminosteroid U74006F on the clinical course of acute experimental allergic encephalomyelitis. Journal of the Neurological Sciences. 135: 18-20. PMID 8926491 DOI: 10.1016/0022-510X(95)00262-Z |
0.331 |
|
| 1996 |
Van Waesberghe JHTM, Castelijns JA, Weerts JGE, Nijeholt GJLA, Hillegers JPM, Polman CH, Barkhof F. Disappearance of multiple sclerosis lesions with severely prolonged T1 on images obtained by a FLAIR pulse sequence Magnetic Resonance Imaging. 14: 209-213. PMID 8847977 DOI: 10.1016/0730-725X(95)02053-V |
0.639 |
|
| 1995 |
Hintzen RQ, Fiszer U, Fredrikson S, Rep M, Polman CH, Lier RAWV, Link H. Analysis of CD27 surface expression on T cell subsets in MS patients and control individuals Journal of Neuroimmunology. 56: 99-105. PMID 7822487 DOI: 10.1016/0165-5728(94)00137-D |
0.331 |
|
| 1995 |
van Oosten BW, Truyen L, Barkhof F, Polman CH. Multiple sclerosis therapy. A practical guide. Drugs. 49: 200-12. PMID 7729328 DOI: 10.2165/00003495-199549020-00005 |
0.528 |
|
| 1995 |
Noort JMv, Sechel ACv, Bajramovic JJ, Ouagmiri ME, Polman CH, Lassmann H, Ravid R. The small heat-shock protein αB-crystallin as candidate autoantigen in multiple sclerosis Nature. 375: 798-801. PMID 7596414 DOI: 10.1038/375798A0 |
0.445 |
|
| 1995 |
Purba JS, Raadsheer FC, Hofman MA, Ravid R, Polman CH, Kamphorst W, Swaab DF. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Neuroendocrinology. 62: 62-70. PMID 7566440 DOI: 10.1159/000126989 |
0.414 |
|
| 1995 |
Polman CH, Hartung H. The treatment of multiple sclerosis: current and future. Current Opinion in Neurology. 8: 200-209. PMID 7551119 DOI: 10.1097/00019052-199506000-00008 |
0.444 |
|
| 1994 |
Harms L, Bock A, JÄnisch W, Valdueza J, Weber J, Link I, De Keyser J, Goossens A, Wilczak N, Vedeler C, Bjorge L, Uvestad E, Conti G, Williams K, Ginsberg L, ... ... Polman CH, et al. Fourth meeting of the European Neurological Society 25-29 June 1994 Barcelona, Spain : Abstracts of Symposia and free communications. Journal of Neurology. 241: 1-164. PMID 26553063 DOI: 10.1007/Bf02333089 |
0.665 |
|
| 1994 |
Polman CH, Barkhof F, van Loenen AC, Lucas CJ, Koetsier JC. [Treatment of multiple sclerosis using recombinant interferon-beta]. Nederlands Tijdschrift Voor Geneeskunde. 138: 7-10. PMID 8289963 |
0.669 |
|
| 1994 |
Polman CH, Koetsier JC. [Current developments in the area of multiple sclerosis]. Nederlands Tijdschrift Voor Geneeskunde. 138: 10-6. PMID 8289951 |
0.691 |
|
| 1994 |
Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Archives of Neurology. 51: 292-6. PMID 8129642 DOI: 10.1001/Archneur.1994.00540150090022 |
0.705 |
|
| 1994 |
Polman CH, Koetsier JC. Cladribine treatment of multiple sclerosis. Lancet. 344: 537; author reply 53. PMID 7980784 DOI: 10.1016/S0140-6736(94)91923-2 |
0.73 |
|
| 1994 |
Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, Koetsier JC. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Archives of Neurology. 51: 1136-9. PMID 7980110 DOI: 10.1001/Archneur.1994.00540230074016 |
0.697 |
|
| 1994 |
Polman CH, Koetsier JC. [Copolymer 1 in the treatment of multiple sclerosis]. Nederlands Tijdschrift Voor Geneeskunde. 138: 2636-7. PMID 7830811 |
0.705 |
|
| 1994 |
Rep M, Hintzen R, Polman C, van Lier R. Functional defects in peripheral blood T cells of multiple sclerosis (MS) patients Journal of Neuroimmunology. 54: 191. DOI: 10.1016/0165-5728(94)90495-2 |
0.354 |
|
| 1994 |
Noort JMv, Sechel ACv, Ouagmiri ME, Bajramovic J, Polman CH, Ravid R. AbstractA small heat shock protein serves as immunodominant T-cell antigen in MS-affected human myelin Journal of Neuroimmunology. 54: 186. DOI: 10.1016/0165-5728(94)90465-0 |
0.364 |
|
| 1993 |
Dijkstra CD, Polman CH, Berkenbosch F. Multiple sclerosis: some possible therapeutic opportunities Trends in Pharmacological Sciences. 14: 124-129. PMID 8516955 DOI: 10.1016/0165-6147(93)90083-V |
0.478 |
|
| 1993 |
Van Diemen HA, Polman CH, Koetsier JC, Van Loenen AC, Nauta JJ, Bertelsmann FW. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clinical Neuropharmacology. 16: 195-204. PMID 8504436 DOI: 10.1097/00002826-199306000-00002 |
0.701 |
|
| 1993 |
Taphoorn MJ, van Someren E, Snoek FJ, Strijers RL, Swaab DF, Visscher F, de Waal LP, Polman CH. Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis. Journal of Neurology. 240: 446-8. PMID 8410088 DOI: 10.1007/Bf00867360 |
0.343 |
|
| 1993 |
van Noort JM, van Sechel A, Boon J, Boersma WJ, Polman CH, Lucas CJ. Minor myelin proteins can be major targets for peripheral blood T cells from both multiple sclerosis patients and healthy subjects. Journal of Neuroimmunology. 46: 67-72. PMID 8360332 DOI: 10.1016/0165-5728(93)90234-P |
0.317 |
|
| 1993 |
van Diemen HA, Polman CH, van Dongen MM, Nauta JJ, Strijers RL, van Loenen AC, Bertelsmann FW, Koetsier JC. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. Journal of the Neurological Sciences. 116: 220-6. PMID 8336169 DOI: 10.1016/0022-510X(93)90329-W |
0.722 |
|
| 1992 |
van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, van Walbeek HK, Koetsier JC. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Annals of Neurology. 32: 123-30. PMID 1510353 DOI: 10.1002/Ana.410320203 |
0.727 |
|
| 1992 |
Hintzen RQ, Polman CH, Lucas CJ, van Lier RA. Multiple sclerosis: immunological findings and possible implications for therapy. Journal of Neuroimmunology. 39: 1-10. PMID 1377708 DOI: 10.1016/0165-5728(92)90169-L |
0.381 |
|
| 1992 |
van Diemen HA, Lanting P, Koetsier JC, Strijers RL, van Walbeek HK, Polman CH. Evaluation of the visual system in multiple sclerosis: a comparative study of diagnostic tests. Clinical Neurology and Neurosurgery. 94: 191-5. PMID 1327607 DOI: 10.1016/0303-8467(92)90088-K |
0.672 |
|
| 1991 |
Barkhof F, Scheltens P, Valk J, Waalewijn C, Uitdehaag BM, Polman CH. Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium- "enhanced" STIR imaging. Neuroradiology. 33: 70-1. PMID 2027451 DOI: 10.1007/Bf00593340 |
0.443 |
|
| 1991 |
Polman CH, van der Wiel HE, Netelenbos JC, Teule GJ, Koetsier JC. A commentary on steroid treatment in multiple sclerosis. Archives of Neurology. 48: 1011-2. PMID 1929889 DOI: 10.1001/Archneur.1991.00530220027012 |
0.748 |
|
| 1991 |
Polman CH, van der Wiel HE. Adrenal function after corticosteroid treatment in MS. Acta Neurologica Scandinavica. 83: 205-7. PMID 1851596 DOI: 10.1111/J.1600-0404.1991.Tb04681.X |
0.427 |
|
| 1991 |
Hintzen RO, van Lier RA, Lucas CJ, Polman CH. Elevated levels of the T-cell activation antigen soluble CD27 in CSF of multiple sclerosis patients Journal of Neuroimmunology. 35: 73. DOI: 10.1016/0165-5728(91)90972-A |
0.342 |
|
| 1990 |
Van der Eerden HA, Koetsier JC, Polman CH. Making a diagnosis in patients with an isolated spinal cord syndrome. Acta Neurologica Scandinavica. 81: 205-8. PMID 2353569 |
0.667 |
|
| 1990 |
Polman CH, van Diemen HA, van Dongen MM, Koetsier JC, van Loenen AC, van Walbeek HK. 4-Aminopyridine in multiple sclerosis. Annals of Neurology. 28: 589. PMID 2082971 DOI: 10.1002/Ana.410280421 |
0.762 |
|
| 1989 |
Matthaei I, Polman CH, de Groot CJ, Dijkstra CD, Koetsier JC, Sminia T. Observer agreement in the assessment of clinical signs in experimental allergic encephalomyelitis. Journal of Neuroimmunology. 23: 25-8. PMID 2786004 DOI: 10.1016/0165-5728(89)90068-4 |
0.652 |
|
| 1989 |
Uitdehaag BM, Polman CH, Valk J, Koetsier JC, Lucas CJ. Magnetic resonance imaging studies in multiple sclerosis twins. Journal of Neurology, Neurosurgery, and Psychiatry. 52: 1417-9. PMID 2614439 |
0.712 |
|
| 1989 |
Polman C, Uitdehaag B, Valk J, Koetsier J. Magnetic resonance imaging in multiple sclerosis twins Clinical Neurology and Neurosurgery. 91: 371. DOI: 10.1016/0303-8467(89)90044-9 |
0.683 |
|
| 1988 |
Dijkstra CD, De Groot CJ, Koetsier JC, Matthaei I, Polman CH, Sminia T. Low-dose cyclosporin A induces relapsing experimental allergic encephalomyelitis in the Lewis rat. Annals of the New York Academy of Sciences. 540: 549-50. PMID 3264682 |
0.608 |
|
| 1988 |
Polman CH, Matthaei I, de Groot CJ, Koetsier JC, Sminia T, Dijkstra CD. Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat. Journal of Neuroimmunology. 17: 209-16. PMID 3257496 DOI: 10.1016/0165-5728(88)90069-0 |
0.627 |
|
| 1988 |
Breukelman AJ, Polman CH, de Slegte RG, Koetsier JC. Neuromyelitis optica (Devic's syndrome): not always multiple sclerosis. Clinical Neurology and Neurosurgery. 90: 357-60. PMID 3233862 DOI: 10.1016/0303-8467(88)90010-8 |
0.705 |
|
| 1987 |
Polman CH, Dijkstra CD, de Groot CJ, Koetsier JC, Sminia T. Presence of Ia-positive cells in the central nervous system of the rat during various pathological conditions. International Archives of Allergy and Applied Immunology. 83: 109-11. PMID 3553033 |
0.634 |
|
| 1987 |
Sminia T, de Groot CJ, Dijkstra CD, Koetsier JC, Polman CH. Macrophages in the central nervous system of the rat. Immunobiology. 174: 43-50. PMID 3471710 DOI: 10.1016/S0171-2985(87)80083-9 |
0.625 |
|
| 1987 |
Rotteveel FT, Kokkelink I, van Walbeek HK, Polman CH, van Dongen JJ, Lucas CL. Analysis of T cell receptor-gene rearrangement in T cells from the cerebrospinal fluid of patients with multiple sclerosis. Journal of Neuroimmunology. 15: 243-9. PMID 3298316 DOI: 10.1016/0165-5728(87)90119-6 |
0.377 |
|
| 1987 |
Polman CH, de Groot CJ, Koetsier JC, Sminia T, Veerman AJ. Cerebrospinal fluid cells in multiple sclerosis and other neurological diseases: an immunocytochemical study. Journal of Neurology. 234: 19-22. PMID 2950211 DOI: 10.1007/BF00314003 |
0.722 |
|
| 1987 |
Polman CH, Koetsier JC, Dijkstra CD, de Groot CJ, Sminia T, Wolters EC, Goudsmit J, van der Helm HJ, de Slegte R, Valk J, Lohman A, Zonneveld F, Crezée F, Venneman W. Scientific meeting of the Amsterdamsche neurologenvereeniging held in Amsterdam, 3rd April 1986 Clinical Neurology and Neurosurgery. 89: 59-60. |
0.589 |
|
| 1986 |
Polman CH, Koetsier JC, Valk J, Wolters EC. Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis. Clinical Neurology and Neurosurgery. 88: 144-5. PMID 3757386 DOI: 10.1016/S0303-8467(86)80012-9 |
0.683 |
|
| 1986 |
Polman CH, Dijkstra CD, Sminia T, Koetsier JC. Immunohistological analysis of macrophages in the central nervous system of Lewis rats with acute experimental allergic encephalomyelitis. Journal of Neuroimmunology. 11: 215-22. PMID 3485656 DOI: 10.1016/0165-5728(86)90005-6 |
0.63 |
|
| 1985 |
Polman CH, Koetsier JC, Wolters EC. Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis. Clinical Neurology and Neurosurgery. 87: 187-92. PMID 4053472 DOI: 10.1016/0303-8467(85)90005-8 |
0.727 |
|
| Show low-probability matches. |
